

Vaccines and Global Health: The Week in Review 27 September 2025 :: Issue 815 Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to <u>david.r.curry@centerforvaccineethicsandpolicy.org</u>.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click <u>here</u> to donate and thank you in advance for your contribution.

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: U.S. Immunization and Public Health Governance/Policy/Funding
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers
- :: Think Tanks
- :: Public Consultations/Call for Inputs/Call for Papers

Milestones, Perspectives

:::::::

Pandemic Accord

<u>Second meeting of the Intergovernmental Working Group (IGWG) on the WHO Pandemic</u> <u>Agreement</u>

15 – 19 September 2025 Hybrid, Geneva, Switzerland Public session webcast recording here

Through resolution WHA78.1, the Health Assembly established an open-ended Intergovernmental Working Group (IGWG) to undertake several tasks. These include, as a priority, drafting and negotiating an annex to the WHO Pandemic Agreement on the Pathogen Access and Benefit Sharing (PABS) system to enable safe, transparent and accountable access and benefit-sharing for PABS materials and sequence information. The Assembly decided that the outcome of this work would be submitted to the Seventy-ninth World Health Assembly in 2026 for its consideration.

::::::::

Member States advance vital work in support of WHO Pandemic Agreement

25 September 2025

News release, Geneva

WHO Member States held their <u>second intergovernmental meeting</u> from 15-19 September, to further develop the **Pathogens Access and Benefit Sharing (PABS) system, a critical annex to the WHO Pandemic Agreement.**

The PABS system aims to enable safe, transparent and accountable access and benefitsharing for pathogen materials and sequence information, as well as equitable, rapid and timely sharing of vaccines, therapeutics, diagnostics and other resulting benefits...

"Countries have taken the next step in building the platform needed for making the world better prepared and safer in the event of future pandemics," said Ambassador Tovar da Silva Nunes of Brazil, co-Chairperson of the IGWG Bureau guiding the negotiations. "There is a strong common understanding on critical issues needed to develop a mechanism for Pathogen Access and Benefit Sharing. Negotiators from around the world have made strong progress in shaping this central pillar of the WHO Pandemic Agreement."

Ambassador da Silva Nunes said the first draft PABS annex was expected to be drafted and negotiated in November and December 2025...

"The amendments to the International Health Regulations and the adoption of the Pandemic Agreement by the World Health Assembly this year were truly generational accomplishments," said Dr Tedros. "Countries now have the opportunity and responsibility to bring the Pandemic Agreement to fruition by finalizing the Pathogen Access and Benefit-Sharing system, as mandated by the World Health Assembly."

In addition to negotiating the PABS annex, the IGWG was established to conduct preparatory work for the Conference of the Parties to the WHO Pandemic Agreement.

::::::::

Global Fund – Eighth Replenishment

Global Fund Celebrates Private Sector Pledges Exceeding US\$1 Billion on Sidelines of UN General Assembly

24 September 2025

NEW YORK/GENEVA – The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) announced **private sector pledges totaling more than US\$1 billion over this last week**, marking a major step forward in its Eighth Replenishment. These commitments – unveiled at the Global Fund's Eighth Replenishment reception today – underscore the private sector's pivotal role in driving forward global health innovation, equity and resilience.

Among the highlights:

- The Gates Foundation pledged US\$912 million at the 2025 Goalkeepers event, bringing its
 total contribution since 2002 to nearly US\$5 billion. This pledge reinforces the Gates Foundation's
 role as the Global Fund's largest private donor and demonstrates its commitment to ending AIDS,
 tuberculosis (TB) and malaria and scaling innovations that could cut child deaths in half again by
 2045.
- (RED) committed US\$75 million, continuing a nearly 20-year partnership with the Global Fund.
- The Children's Investment Fund Foundation (CIFF) pledged US\$50 million to accelerate the introduction and rollout of innovative TB diagnostics its first-ever investment in TB in addition to its earlier US\$150 million commitment to break the cycle of HIV transmission.
- Goodbye Malaria renewed its partnership with the Global Fund with a new US\$5.5 million commitment to help eliminate malaria in Eswatini, Mozambique and South Africa.
- The Johnson & Johnson Foundation announced a US\$5 million pledge to the Africa Frontline First Catalytic Fund (AFF-CF) to accelerate the scale-up of professionalized community health workers across Africa.

:::::::

Gates Foundation

With Millions of Children's Lives on the Line, Bill Gates Says Humanity Is at a Crossroads

- :: At 2025 Goalkeepers event, Gates lays out **roadmap for saving millions more children's lives by 2045** if governments stretch every dollar and scale a pipeline of affordable, lifesaving innovations
- :: Announces **new pledge to the Global Fund 2026-2028** replenishment to prevent deaths from AIDS, TB, and malaria
- :: **Honors President of the Government of Spain** with 2025 Global Goalkeeper Award and 10 champions for their ingenuity and resilience, and for offering hope, solutions in the face of steep funding cuts

NEW YORK (September 22, 2025) – **At its 2025 Goalkeepers event, Gates Foundation** Chair Bill Gates stood before an audience of more than 1,000 global government, community, philanthropy, and private-sector leaders and issued a stark but hopeful call to world leaders: save millions of children's lives and make some of the deadliest diseases history by 2045.

"Humanity is at a crossroads. With millions of children's lives on the line, global leaders have a once-in-a-generation chance to do something extraordinary," said Gates. "The choices they make now—whether to go forward with proposed steep cuts to health aid or to give the world's children the chance they deserve to live a healthy life—will determine what kind of future we leave the next generation."

This year, donor countries dealing with domestic challenges, high debt levels, and aging populations made dramatic funding cuts to global development assistance for health (DAH). According to a recent study by the Institute for Health Metrics and Evaluation (IHME), global DAH fell by 21% between 2024 and 2025, and is now at a 15-year low.

With key global health funding decisions expected before the end of the year, total funding levels could rise. However, if the current cuts hold, they threaten decades of progress that saw child mortality cut in half since 2000—from 10 million children to less than 5 million children a year—one of humanity's greatest achievements.

During the annual event, which this year focused on reigniting a shared commitment to saving children's lives, **Gates announced his foundation's pledge of \$912 million over three years to the Global Fund** to Fight AIDS, Tuberculosis and Malaria's 2026-2028 replenishment. The Global Fund is one of the most effective lifesaving initiatives of the 21st century. Its fundraising replenishment cycle ends this November, underscoring the urgency for governments to make pivotal decisions in the coming weeks and months for the lives of millions of people.

"What's happening to the health of the world's children is worse than most people realize, but our longterm prospects are better than most people can imagine," said Gates. "I don't expect most governments to suddenly restore foreign aid to historic levels, but I am an optimist, and I believe governments can and will do what's needed to save as many children as possible," said Gates.

With shrinking global health budgets as the backdrop, the Goalkeepers event highlighted the people, science and innovations, and policies that are accelerating solutions for how leaders can do more with less.

A Roadmap to a Healthier Future

"We have a roadmap for saving millions of children and making some of the deadliest childhood diseases history by 2045," Gates asserted. "I'm urging world leaders to invest in the health of all people, especially children, to deliver this future."

Results from work by the Gates Foundation and the IHME indicate that sustaining global investments in child health and scaling lifesaving innovations could cut child deaths in half again over the next 20 years. The roadmap includes:

- Renewing investments in proven initiatives, such as the Global Fund and Gavi, the
 Vaccine Alliance, to help countries make smarter, more cost-effective health decisions; gain access
 to proven vaccines, medicines, and treatments; and focus on sustainability and transitioning to selfreliance
- **Prioritizing primary health care systems**—even in the face of challenging budget decisions—to prevent, detect, and treat childhood illnesses early
- Investing in further R&D and effectively rolling out breakthrough innovations that include:
 - :: A suite of new approaches to combating malaria, including innovations that prevent mosquitoes from carrying parasites and single-dose treatments to accelerate eradication of the disease
 - :: **Long-acting HIV drugs and prevention options** that replace daily pills to drive AIDS deaths down to single digits

:: **New maternal vaccines** against respiratory syncytial virus (RSV) and group B streptococcus (GBS) that have the potential to protect babies from deadly respiratory illnesses :: **Artificial intelligence** to leverage smarter, faster, and cheaper delivery of safe, cost-effective medicines to dramatically improve lives

A New Three-Year Commitment to the Global Fund

Since 2002, the Global Fund has saved more than 70 million lives; reduced deaths from AIDS, TB, and malaria by more than 60%; and strengthened global health security. Each dollar invested in the Global Fund delivers an estimated \$19 in health and economic returns.

The foundation's new pledge [US\$912 million[brings its total commitments to the Global Fund to \$4.9 billion since 2002, making it one of the foundation's largest investments. The pledge aims to galvanize governments, philanthropists, and the private sector to come to the table with significant investments for the fund's Eighth Replenishment, which is co-hosted by South Africa and the United Kingdom. With millions of lives on the line, the level of investment in the Global Fund over the next three years will determine whether the world saves millions of lives; curbs HIV, TB, and malaria; and bolsters economies and global health security...

::::::::

<u>Gates Foundation Partners With Indian Manufacturer to Drive Down Cost of, Accelerate</u> Access to Groundbreaking HIV Prevention Tool

New partnership will join others to expand access to generic lenacapavir for millions more people at risk of HIV in high-burden countries—bringing the world closer to ending the epidemic

NEW YORK (September 24, 2025) – Millions more people at risk of HIV in low- and middle-income countries (LMICs) will have access to a powerful new prevention option: a low-cost, generic version of lenacapavir, the world's first twice-yearly injectable pre-exposure prophylaxis (PrEP).

A new partnership announced today between the Gates Foundation and Indian manufacturer Hetero Labs (Hetero)—supported by upfront funding and volume guarantees—will enable the company to manufacture generic lenacapavir at roughly \$40 per patient per year (after a short pre-treatment oral regimen), a price point designed to make the breakthrough treatment affordable for national health systems...

In a parallel move today, **Unitaid, the Clinton Health Access Initiative (CHAI), and Wits RHI** <u>announced</u> new commitments with Dr. Reddy's Laboratories Ltd. (DRL), another Indian manufacturer, reinforcing efforts to build a competitive generics ecosystem. The accelerated development of a large-scale generic supply of lenacapavir, which is anticipated as early as 2027 pending regulatory approval, will reduce the time between initial doses and provide wider access to the drug. This move could potentially transform the fight against HIV and help end the epidemic faster and more equitably.

The new collaborations complement <u>agreements</u> <u>already in place</u> between the Global Fund to Fight AIDS, Tuberculosis and Malaria; Gilead Sciences; and the U.S. State Department through <u>PEPFAR</u>, and supported by the Children's Investment Fund Foundation (CIFF), to roll out the initial supply of lenacapavir in LMICs, potentially reaching countries as early as the end of 2025...

Autism – Causation/Research/Vaccines

WHO statement on autism-related issues

24 September 2025 Statement

The World Health Organization (WHO) emphasizes that there is currently no conclusive scientific evidence confirming a possible link between autism and use of acetaminophen (also known as paracetamol) during pregnancy.

Globally, nearly 62 million people (1 in 127) have autism spectrum disorder, a diverse group of conditions related to development of the brain. Although awareness and diagnosis have improved in recent years, the exact causes of autism have not been established, and it is understood there are multiple factors that can be involved.

Extensive research has been undertaken over the past decade, including large-scale studies, looking into links between acetaminophen use during pregnancy and autism. At this time, no consistent association has been established.

WHO recommends that all women continue to follow advice of their doctors or health workers, who can help assess individual circumstances and recommend necessary medicines. Any medicine should be used with caution during pregnancy, especially in the first three months, and in line with advice from health professionals.

Also, a robust, extensive evidence base exists showing childhood vaccines do not cause autism. Large, high-quality studies from many countries have all reached the same conclusion. Original studies suggesting a link were flawed and have been discredited. Since 1999, independent experts advising WHO have repeatedly confirmed that vaccines—including those with thiomersal or aluminum—do not cause autism or other developmental disorders.

Childhood vaccine schedules are developed through a careful, extensive and evidence-based process involving global experts and country input. The childhood immunization schedule, carefully guided by WHO, has been adopted by all countries, and has saved at least 154 million lives over the past 50 years. The schedule remains essential for the health and wellbeing of every child and every community. These schedules have continually evolved with science and now safeguard children, adolescents and adults against 30 infectious diseases.

Every vaccine recommendation by the Strategic Advisory Group of Experts on Immunization (SAGE), an independent advisory group to WHO, is grounded in rigorous review of evidence and carefully designed to offer the best protection against serious diseases and to be delivered when most needed.

When immunization schedules are delayed or disrupted, or altered without evidence review, there is a sharp increase in the risk of infection not only for the child, but also for the wider community. Infants too young to be vaccinated and people with weakened immune systems or underlying health conditions are at greatest risk.

Autism and neurodevelopmental disorders are among priority mental health and neurological conditions being discussed at the 4th UN High-Level Meeting on NCDs and mental health this Thursday, 25 September. As a global community, we need to do more to understand the causes of autism and how best to care for and support the needs of autistic people and their families.

WHO is committed to advancing this goal working together with partners including autistic-led organizations and other organizations representing persons with lived experience. WHO also stands

with people who are living with autism and their families, a dignified community entitled to evidencebased considerations free of stigma.

:::::::

FACT: Evidence Suggests Link Between Acetaminophen, Autism

The White House, USA September 22, 2025

Today, President Donald J. Trump joined Administration officials to announce major progress in understanding the root causes of autism, which has <u>exploded</u> in diagnoses over the past two decades, and unveil <u>bold new initiatives</u> to tackle the autism epidemic.

Predictably, the Fake News immediately went into frenzied hyperventilation with their usual smears, distortions, and lies...

<u>President Trump, Secretary Kennedy Announce Bold Actions to Tackle Autism Epidemic</u>

HHS Media Release,

WASHINGTON—SEPTEMBER 22, 2025

FDA Responds to Evidence of Possible Association Between Autism and Acetaminophen Use During Pregnancy

Agency initiates safety label change and notifies physicians of possible link September 22, 2025

The U.S. Food and Drug Administration today initiated the process for a label change for acetaminophen (Tylenol and similar products) to reflect evidence suggesting that the use of acetaminophen by pregnant women may be associated with an increased risk of neurological conditions such as autism and ADHD in children. The agency also issued a related <u>letter alerting physicians</u> nationwide.

"The FDA is taking action to make parents and doctors aware of a considerable body of evidence about potential risks associated with acetaminophen," said FDA Commissioner Marty Makary, M.D., M.P.H. "Even with this body of evidence, the choice still belongs with parents. The precautionary principle may lead many to avoid using acetaminophen during pregnancy, especially since most low-grade fevers don't require treatment. It remains reasonable, however, for pregnant women to use acetaminophen in certain scenarios."

Evidence in recent years has suggested a correlation between acetaminophen use during pregnancy and subsequent diagnosis of conditions like autism and ADHD. Multiple large-scale cohort studies, including the <u>Nurses' Health Study II</u> and the <u>Boston Birth Cohort</u>, find this association. Some studies have described that the risk may be most pronounced when acetaminophen is taken chronically throughout pregnancy.

It is important to note that while an association between acetaminophen and neurological conditions has been described in many studies, a causal relationship has not been established and there are contrary studies in the scientific literature. It is also noted that acetaminophen is the only over-the-counter drug approved for use to treat fevers during pregnancy, and high fevers in pregnant women can pose a risk to their children. Additionally, aspirin and ibuprofen have well-documented adverse impacts on the fetus.

CDC - Notice of Intent to Sole Source to Rensselaer Polytechnic Institute

Active [SAM.gov, was made by the CDC Office of Acquisition Services]

Notice ID: 75D30125Q78752

Response Date: Sep 26, 2025 10:00 AM EDT

Product Service Code: B524 - SPECIAL STUDIES/ANALYSIS- MATHEMATICAL/STATISTICAL NAICS Code: 541715 - Research and Development in the Physical, Engineering, and Life Sciences

(except Nanotechnology and Biotechnology)

Description

The Centers for Disease Control and Prevention intends to award a sole source firm fixed price contract to Rensselaer Polytechnic Institute for Investigation of the Association between Vaccinations and Autism Prevalence. The vendor has unique ability to link children to maternal cohorts using proprietary databases and de-identified data sets, enabling advanced statistical analyses within the project's timeframe. This contract action is for services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 6.302-1. All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.

This notice of intent is not a request for competitive quotations; however, all quotations/responses received within 15 of days of the issuance of this notice shall be considered by the government. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to contract specialist at contracts@cdc.gov by 9/26/25 and must include "75D30125Q78752" in the subject line of the email.

[System for Award Management (SAM.gov) is an official website of the U.S. Government]

:::::::

AAP Statement on White House Autism Announcement

September 22, 2025, American Academy of Physicians

Today's White House event on autism was filled with dangerous claims and misleading information that sends a confusing message to parents and expecting parents and does a disservice to autistic individuals.

AAFP: Linking Vaccines to Autism is Unproven and Dangerous

Sep 22, 2025 — American Academy of Family Physicians

Vaccines do not cause autism. Decades of rigorous research have failed to provide credible scientific evidence linking vaccines to autism. Vaccines are among the most effective tools we have to keep people, especially infants and children, healthy and out of hospitals. Continued claims about a vaccineautism link risk public health by causing people to delay or defer vaccination out of fear.

There is also no credible body of evidence linking acetaminophen (commonly known as Tylenol) use in pregnancy to autism. The claim is unfounded and has been refuted by rigorous studies and systematic reviews...

SMFM Response to Administration Announcement on Acetaminophen Use During Pregnancy and Autism

In response to today's White House press conference announcement, The Society for Maternal-Fetal Medicine (SMFM) reiterates its recommendation advising both physicians and patients that acetaminophen is an appropriate medication to treat pain and fever during pregnancy. Date posted - 09/22/2025

PhRMA Statement on Autism

WASHINGTON, D.C. (September 22, 2025) – Pharmaceutical Research and Manufacturers of America (PhRMA) Chief Medical Officer Dr. Michael Ybarra issued the following statement:

"Parents of children with autism want the best for their kids and ongoing research on the underlying causes and treatments are essential to provide the answers they deserve.

"Importantly, a vast body of scientific research has thoroughly debunked claims linking vaccines, their ingredients or the childhood immunization schedule to autism, and today's announcement does not change that."

Read more about decades of	research	finding n	o link i	between	vaccines and	autism.

Polio – PHEIC

:::::::

Polio this week [24 September 2025]

Headlines [Selected]

GPEI donors and partners reaffirm commitment to end polio

Senior global health leaders met this week to discuss the final push to eradicate polio in a side event of the 80th United Nations General Assembly. The event, 'United to Finish the Job: High Level Side-Event on Polio Eradication', co-hosted by the King Salman Humanitarian Aid and Relief Centre (KSRelief), UNICEF, the World Health Organization (WHO) and the Global Polio Eradication Initiative (GPEI), addressed the urgent need to end wild polio transmission in Afghanistan and Pakistan while strengthening response to variant poliovirus outbreaks in fragile settings across Africa and Asia. More.

Polio eradication – not time to quit, time to recommit

Ziad Memish, advisor to the Supervisor General of KSRelief for Medical & Humanitarian Research, and Hamid Jafari, Director for Polio Eradication in WHO's Eastern Mediterranean Region, published a piece in Arab News highlighting the importance of solidarity, resources and Saudi Arabia's historic US\$500 million pledge. Read the piece <a href="https://example.com/hemister/

Latest IMB report published

The IMB released its 24th report, following its July meeting. The report, and GPEI's response statement, are both available here.

WHO DG Dr Tedros on partners' commitment to polio eradication

At Sunday's GPEI Polio Oversight Board (POB) meeting, WHO Director-General Dr Tedros Adhanom Ghebreyesus spoke of partners' commitment to ending polio and the importance of building on polio investments to help strengthen broader health systems. Read more here.

Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: two WPV1 cases and 50 WPV1-positive environmental samples

- Algeria: one cVDPV2-positive environmental sample

Angola: three cVDPV2 casesNigeria: four cVDPV2 cases

:::::::

GPEI donors and partners reaffirm commitment to end polio

High-level side event highlights urgent need to protect children in Afghanistan, Pakistan and conflict zones

NEW YORK (22 September 2025) — Senior global health leaders met today to discuss the final push to eradicate polio in a side event of the 80th United Nations General Assembly.

The event, 'United to Finish the Job: High Level Side-Event on Polio Eradication', co-hosted by the King Salman Humanitarian Aid and Relief Centre (KSRelief), UNICEF, the World Health Organization (WHO) and the Global Polio Eradication Initiative (GPEI), addressed the urgent need to end wild polio transmission in Afghanistan and Pakistan while strengthening response to variant poliovirus outbreaks in fragile settings across Africa and Asia.

The high-level convening at UNICEF House brought together governments, international organizations and civil society representatives to share progress on the current state of global polio

eradication. Participants discussed sustaining access to every child, building community trust and securing resources, even amid urgent humanitarian crises, from parts of Pakistan and Afghanistan to Somalia and Yemen.

GPEI partner leadership emphasized the importance of sustained funding to finishing the job, highlighting the Kingdom of Saudi Arabia's US \$500 million pledge to the GPEI, announced in April 2024. These and other critical donor funds are helping the partnership to reach hundreds of millions of children each year with lifesaving polio vaccines and end transmission of the virus for good...

::::::::

<u>THE GLASS MOUNTAIN – ONLY FRESH THINKING WILL NOW DELIVER A POLIO-FREE</u> WORLD

24th Report of the Independent Monitoring Board – GPEI

SEPTEMBER 2025 :: 154 pages

Conclusions [30 pages]

In headline terms, 2024 was a year of poor performance for the Polio Programme in the two remaining endemic countries. It was also a story of failed expectations...

[Excerpt: p. 116 ff]]

...Growing geopolitical complexity and major shifts in global health policy and funding are having huge effects on the Polio Programme. It is confronting a stark financial reality: transitioning from \$1 billion to \$750 million annually—a 32-35% reduction—while maintaining eradication standards that have proven elusive even at higher funding levels. This represents the most significant challenge in the programme's history, forcing fundamental questions about operational sustainability and strategic priorities.

Decades of missed goals have triggered a deeper questioning of who is driving decisionmaking within GPEI and how accountability will be activated so that transformational changes can take place. This is being considered as part of an external governance review, the outcome of which will be discussed by the Polio Oversight Board in late-September 2025.

FINANCIAL SHOCKWAVES AND LONGSTANDING ACCOUNTABILITY WEAKNESSES

The United States government's health and international development funding decisions, and consequent changes to organisational structures, policies and purposes, represents an unprecedented challenge to global polio eradication. There are immediate severe operational impacts and long-term strategic implications that affect the Polio Programme and services that work with, and support, it. The overall disruption threatens to further delay eradication timelines and increase long term costs.

The response from alternative donors, particularly the Kingdom of Saudi Arabia, demonstrates the potential for burden-sharing, but cannot fully compensate for the scale and institutional significance of the United States withdrawal.

The success of Congressional advocacy work and the ultimate 2026 financial year appropriation decisions will determine whether this crisis represents a temporary disruption or a fundamental reordering of global health priorities. The stakes extend beyond polio eradication to encompass broader questions of global health governance, disease surveillance capabilities, and the United States' role in international health security.

As a founding partner of the Global Polio Eradication Initiative (GPEI), the changes made to CDC are of deep concern. They raise fundamental questions about the United States' continued commitment to polio eradication and broader international health cooperation.

As one of six core partners in GPEI alongside WHO, Rotary International, UNICEF, the Gates Foundation, and Gavi, the CDC has historically provided crucial scientific and technical expertise to the initiative. The agency's contributions have included operating specialised polio laboratories, providing genomic sequencing capabilities, deploying field epidemiologists (through the STOP programme), and maintaining surveillance systems essential for outbreak detection and response.

The proposed elimination of the CDC's nearly \$200 million Polio Programme would represent a devastating blow to GPEI's operations. This funding has supported critical activities including laboratory surveillance, field operations, and technical assistance to endemic countries. The CDC's Polio and Picornavirus Laboratory is a WHO Global Specialized Laboratory and provides essential diagnostic services and genomic sequencing that guides eradication strategies.

Moreover, the broader cuts to global health programmes signal a fundamental retreat from America's historical leadership role in international health cooperation...

...EXISTENTIAL QUESTIONS AND THE TEST OF COMMITMENT

While the magnitude of funding losses creates genuine risks to programme continuity and eradication timelines, the crisis also forces long overdue examinations of resource allocation efficiency, performance accountability, and strategic prioritisation.

Success in navigating this crisis requires balancing immediate operational needs with longer term strategic positioning. Short-term resource mobilisation and operational adjustments must support sustainable funding models and enhanced performance management systems that can function effectively in a more constrained resource environment.

The stakes could not be higher—not only for the millions of children at risk of paralysis, but for the credibility of global health governance itself. The coming year will test the resilience, adaptability, and commitment of the global health community as never before.

The glass mountain of polio eradication has proven unclimbable through traditional approaches. Fresh thinking, institutional courage, strategic realism, broader programme design, and unambiguous country buy-in are the only remaining paths to the peak.

Recommendations [22 recommendations covered in 7 pages]

The recommendations that follow address systemic weaknesses in the global architecture of polio eradication that have enabled persistent transmission to continue despite decades of effort and billions of dollars invested.

While much of this report documents continued challenges in Pakistan, Afghanistan, and Nigeria—the major countries where poliovirus circulation persists—the IMB has deliberately focused its formal recommendations on structural and strategic changes that transcend individual country programmes (with some exceptions).

This approach reflects a reality: the fundamental barriers to eradication are not only technical deficits that can be resolved through country-specific guidance, but rather systemic failure in accountability, integration, resource allocation, and strategic coherence that characterise the global programme itself...

[Excerpt]

...Recommendation 4. Commission and publish a comprehensive impact assessment of US government funding cuts and institutional changes on global polio eradication prospects.

The withdrawal of US funding represents the most significant disruption in GPEI history, yet the Polio Programme lacks a publicly available systematic assessment of cascading impacts beyond immediate budget shortfalls. A comprehensive impact statement should quantify not only direct financial losses (plus USAID and CDC contributions) but also the operational consequences of losing technical expertise, laboratory capabilities, surveillance coordination, and institutional knowledge accumulated over decades.

The assessment should identify which technical functions and human resources have been lost or degraded and the planned alternative arrangements. This analysis is essential for donor confidence, strategic planning, and ensuring that mitigation strategies address actual rather than assumed vulnerabilities. The impact statement should be published transparently to demonstrate accountability and inform immediate strategic and operational policies, plans and decisions...

:::::::

<u>GPEI Statement – 24th IMB Report "The Glass Mountain"</u>

GPEI Welcomes 24th Annual Report from the Independent Monitoring Board 22/09/2025

::::::::

Cholera

<u>Multi-country outbreak of cholera, external situation report #30 -26 September 2025</u> Edition 30

26 September 2025 | *Emergency situation update*

PDF: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20250926 multi-country_outbreak-of-cholera_sitrep_-30.pdf?sfvrsn=602c31ad_4&download=true

Overview

From 1 January to 31 August 2025, a cumulative total of 462 890 cholera cases and 5869 deaths were reported from 32 countries across five WHO regions, with the Eastern Mediterranean Region recording the highest numbers, followed by the African Region, the South-East Asia Region, the Region of the Americas, and the Western Pacific Region. No cases were reported in the European Region.

In August 2025 (epidemiological weeks 32 to 35), a total of 57 215 new cholera and acute watery diarrhoea cases were reported from 23 countries, territories, areas (hereafter countries) across three WHO regions, showing a 16% decrease from July. The period also saw 758 cholera-related deaths globally, a 22% decrease from the previous month.

In August 2025, the average stockpile of oral cholera vaccine was 2.6 million doses, below the emergency stockpile level of five million.

Cholera upsurge (2021-present): https://www.who.int/emergencies/situations/cholera-upsurge/

:::::::

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: U.S. Immunization and Public Health Governance/Policy/Funding

:: Organization Announcements

:: <u>Journal Watch</u>

:: Pre-Print Servers

:: Think Tanks

:: Public Consultations/Call for Inputs/Call for Papers

::::::::

WHO & Regional Offices [27 Sep 2025]

https://www.who.int/news

Selected News/Announcements/Statements

26 September 2025 News release

<u>World leaders show strong support for political declaration on noncommunicable diseases</u> and mental health

26 September 2025 Departmental update

New study reveals sex life impacts are major reasons for contraceptive discontinuation

26 September 2025 Departmental update

Countries and global leaders recognized for their action to tackle the obesity crisis

26 September 2025 News release

Recommendations announced for influenza vaccine composition for the 2026 southern hemisphere influenza season

25 September 2025 News release

Member States advance vital work in support of WHO Pandemic Agreement

25 September 2025 Departmental update

Updated WHO dashboard offers new insights on antimicrobial resistance and use

25 September 2025 Departmental update

Contraceptive use: a catalyst for women's health and socioeconomic empowerment

25 September 2025 Departmental update

Core funders of medical research commit to strengthening clinical trials worldwide

Some of the world's largest funders of medical research have today committed, through the signature of a <u>joint statement</u>, to implement WHO standards to strengthen clinical trial systems and ensure that research better serves patients and communities. The statement sets out measures to integrate clinical trials into sustainable national infrastructure, improve trial design, ensure that trial populations are representative, and embed best practices on transparency, data management and public engagement.

The move builds on the momentum of the recent launch of WHO's Guidance for Best Practices for Clinical Trials and the Global Action Plan for Clinical Trial Ecosystem Strengthening (GAP-CTS). The statement also draws on the 2017 WHO joint statement on public disclosure of results from clinical trials and the 2023 Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) funders' roadmap for clinical trial coordination...

25 September 2025 Departmental update

WHO Traditional Medicine Global Library to launch in 2025

<u>Countries making unprecedented efforts, but billions still lack basic services in health care facilities - WHO/UNICEF new report warns</u>

24 September 2025 Statement

WHO statement on autism-related issues

23 September 2025 News release

Uncontrolled high blood pressure puts over a billion people at risk

EU renews support for WHO's Universal Health Coverage Partnership

22 September 2025 Departmental update

Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO - September 2025

::::::::

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: 22 September 2025

Angola strengthens Ebola outbreak preparedness measures

WHO Region of the Americas PAHO

:: 25 Sep 2025

<u>Health Ministers of the Americas to meet in Washington to set regional health priorities at PAHO's 62nd Directing Council</u>

From September 29 to October 3, discussions will focus on noncommunicable diseases, access to high-cost health technologies, and more. The new PAHO Strategic Plan is also expected to be approved. Washington, D.C., September 25, 2025 (PAHO) – Top health authorities from across the Region of the Americas will gather at the headquarters of the Pan...

:: 22 Sep 2025

At UNGA 80 event, PAHO Director highlights critical link between infectious diseases and NCDs

New York, 22 September 2025 (PAHO) – The urgent need to address the interplay between infectious diseases and non-communicable diseases (NCDs), which together pose the greatest public health challenges in the Americas, was highlighted by Dr. Jarbas Barbosa, Director of the Pan American Health Organization (PAHO), at an event held on the sidelines...

:: 25 Sep 2025

Health Ministers of the Americas to meet in Washington to set regional health priorities at PAHO's 62nd Directing Council

From September 29 to October 3, discussions will focus on noncommunicable diseases, access to high-cost health technologies, and more. The new PAHO Strategic Plan is also expected to be approved. Washington, D.C., September 25, 2025 (PAHO) – Top health authorities from across the Region of the Americas will gather at the headquarters of the Pan...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

No new digest content identified.

WHO Eastern Mediterranean Region EMRO

:: Cholera vaccination campaign launched in Darfur to protect over 1.8 million people 24 September 2025

WHO Western Pacific Region

No new digest content identified.

::::::

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

26 September 2025

Multi-country outbreak of cholera, external situation report #30 -26 September 2025

26 September 2025

Public Health Situation Analysis - Cabo Verde Hurricane Erin

::::::

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

No new digest content identified.

::::::

Weekly Epidemiological Record

Vol. 100, No. 39, pp. 411-438 26 September 2025

https://www.who.int/publications/journals/weekly-epidemiological-record

:: WHO position paper: Pneumococcal conjugate vaccines in infants and children aged <5 years – September 2025

:::::::

New WHO Publications

https://www.who.int/publications

Selected

27 September 2025

<u>Integrative review of national health literacy policy blueprints as a tool for change toward health literate systems</u>

24 September 2025

A decision framework for effective, equitable and context-specific public health and social measures...

23 September 2025

Availability, price and affordability of health technologies for the management of diabetes

23 September 2025

Global report on hypertension 2025: high stakes: turning evidence into action

Africa

Africa CDC [27 Sep 2025]

https://africacdc.org/

Press Releases, Statements [Selected]

Africa CDC Welcomes UK's Formal Approval of Direct Funding Following Successful Due Diligence Assessment

24 September 2025

... following nearly one year of rigorous Due Diligence Assessment, the United Kingdom has formally approved direct funding to Africa CDC as the framework for partnership. This decision marks a new era of confidence and collaboration, underscoring trust in Africa CDC's strengthened fiduciary and governance systems...

Press Releases

A New Day for Children with Sickle Cell Disease: Africa CDC Calls for Urgent Action at UN 24 September 2025

Press Releases

<u>Africa CDC to boost NCD Surveillance across 10 countries in East and Southern Africa</u> 23 September 2025

Decisions

<u>Decision of the Committee of Heads of State and Government of Africa CDC Extraordinary Session on the Margins of UNGA 80</u>

22 September 2025

::::::

China - CDC+

http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China [27 Sep 2025]

http://en.nhc.gov.cn/

News

No new digest content identified.

National Medical Products Administration – PRC [27 Sep 2025]

http://english.nmpa.gov.cn/

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (7) 2025-09-26 / No. 39 WORLD RABIES DAY ISSUE

PDF of this issue

:: Foreword: Let's Act Now to Make Rabies History

- :: Vital Surveillances: Surveillance and Analysis of Animal Rabies China, 2004–2024
- :: <u>Preplanned Studies: Efficacy Evaluation of Virus Clearance of SYN023 in A Murine Rabies Model China, 2025</u>
- :: <u>Preplanned Studies: Active Surveillance on Safety and Compliance of Freeze-dried Human Rabies Vaccine (Vero Cell) Jiangsu Province, China, 2023–2024</u>
- :: <u>Preplanned Studies: Metagenomic Next-Generation Sequencing Unmasks Atypical Rabies Guangxi Zhuang Autonomous Region, China, 2024</u>
- :: <u>Review: The Clinical Advantages of Anti-Rabies Monoclonal Antibodies in Post-Exposure Prophylaxis</u>
 Worldwide, 2016–2025

::::::

Europe

European Centre for Disease Prevention and Control

https://www.ecdc.europa.eu/en

News/Updates/Reports/Publications [Selected]

Tools to promote vaccination acceptance and uptake now available in all official EU/EEA languages

22 Sep 2025

Surveillance and monitoring

Communicable disease threats report, 20 - 26 September 2025, week 39

26 Sep 2025

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 20 - 26 September 2025 and includes updates on respiratory viruses, swine influenza, West Nile virus infection, dengue, chikungunya, Crimean-Congo haemorrhagic fever and Ebola.

Surveillance and monitoring

Seasonal surveillance of dengue in the EU/EEA

26 Sep 2025

Update providing weekly overview of the countries and areas where dengue cases have been reported.

Surveillance and monitoring

Seasonal surveillance for chikungunya virus disease in the EU/EEA for 2025

26 Sep 2025

Update providing weekly overview of the countries and areas where chikungunya virus disease cases have been reported.

European Medicines Agency [EMA]

https://www.ema.europa.eu/en/news

News & Press Releases

New targets for clinical trials in Europe

500 authorised multinational clinical trials to be added over five years

23 September 2025

The European Commission (EC), the Heads of Medicines Agencies (HMA) and EMA have jointly developed two new targets for clinical trials, to monitor progress against the ambition to make the European Union (EU) a more attractive destination for clinical research and improve timely access to innovative medicines for patients. In five years, the aim is that:

• An additional 500 multinational clinical trials are added to the current average of 900 that are already authorised each year (i.e. an estimated 100 per year).

 Two thirds (66%) of clinical trials should begin recruiting patients within 200 calendar days or less from the date of application submission. This is in comparison to only 50% of clinical trials today.

These ambitious goals build on ongoing efforts to create a more supportive environment for clinical research. A key part of this is the Accelerating Clinical Trials in the EU (ACT EU) initiative, a collaboration between EC, HMA and EMA, which seeks to optimise how clinical trials are designed and run.

::::::::

India

National Centre for Disease Control

Directorate General of Health Services, Ministry of Health & Family Welfare Announcements

World Rabies Day, 28 Sep 2025

U.S. Immunization and Public Health Governance/Policy/Funding

Given the continuing extraordinary situation in the U.S., we have established a separate section of the digest to capture and organize key content. Please note that we will selectively include external analysis and comment, indenting this content under the relevant organization/action. We recognize that despite the volume of content in this section, this summary is indicative and not exhaustive.

White House, HHS, FDA, CDC+

White House

<u>Presidential Actions – Executive Orders; Memoranda; Proclamations</u> No new digest content identified.

Department of State

Press Releases

No new digest content identified.

NIH

News Releases

NIH establishes nation's first dedicated organoid development center to reduce reliance on animal modeling

September 25, 2025 — The Standardized Organoid Modeling Center aims to produce standardized protocols for organoid research, addressing reproducibility challenges.

NIH launches \$50M Autism Data Science Initiative to unlock causes and improve outcomes

September 22, 2025 — Funded projects will drive discoveries across biology, environment, and autism services.

FDA

Press Announcements

<u>September 22, 2025 - FDA Responds to Evidence of Possible Association Between Autism and Acetaminophen Use During Pregnancy</u>

<u>September 22, 2025 - FDA Takes Action to Make a Treatment Available for Autism Symptoms</u>

FDA CBER

Latest News

No new digest content identified.

FDA VRBPAC [Vaccines and Related Biological Products Advisory Committee] Advisory Committee Calendar

<u>Vaccines and Related Biological Products Advisory Committee October 9, 2025</u> Meeting Announcement - 10/09/2025

... Under Topic I, the Committee will discuss and make recommendations on the strain selection for the influenza virus vaccines for the 2026 Southern Hemisphere influenza season. Under Topic II, the Committee will discuss and make recommendations on advancing CBER's allergen standardization program...

FDA Pediatric Advisory Committee Meeting

Advisory Committee Calendar

Advisory Committee Calendar has no meetings posted for this Advisory Committee

CDC

http://www.cdc.gov/media/index.html
Latest News
No relevant media releases identified.

ACIP

Meeting - September 18-19, 2025

- Final ACIP September 18-19, 2025 Meeting Agenda (posted 9-19-2025)
- Anticipated Votes
- ACIP Presentation Slides: September 18-19, 2025 Meeting
- YouTube Live Stream Link 9-18-2025
- YouTube Live Stream Link 9-19-2025
- Written Public Comments

MMWR Weekly

https://www.cdc.gov/mmwr/index2025.html

September 25, 2025 / No. 36

PDF of this issue

- <u>Pediatric Influenza-Associated Encephalopathy and Acute Necrotizing Encephalopathy —</u> United States, 2024–25 Influenza Season
- Influenza-Associated Pediatric Deaths United States, 2024–25 Influenza Season
- <u>Interim Effectiveness Estimates of 2025 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Outpatient and Hospitalized Illness Eight Southern Hemisphere Countries, March—September 2025</u>

National Vaccine Program Committee (NVAC)

https://www.hhs.gov/vaccines/about/index.html

Upcoming Meetings/Latest Updates

No 2025 meeting dates posted.

Advisory Commission on Childhood Vaccines (ACCV)

https://www.hrsa.gov/advisory-committees/vaccines/meetings

Next ACCV Meeting - TBD [To be re-scheduled from original date January 29, 2025]

.....

NSF

News

NSF invests \$30M in EPSCoR jurisdictions for research and workforce development in energy, semiconductors, nanotechnology and biotechnology
September 26, 2025

:::::::

U.S. Congress

U.S. Senate

Senate Health, Education, Labor, and Pensions (HELP) Committee No new digest content identified.

:::::::

Supreme Court, Federal Appellate Courts

<u>Supreme Court - DEPARTMENT OF STATE, ET AL. v. AIDS VACCINE ADVOCACY COALITION</u> <u>ET AL</u>

Supreme Court Allows Trump to Slash Foreign Aid

The court's conservative majority allowed the president to cut the funding in part because it said his flexibility to engage in foreign affairs outweighed "the potential harm" faced by aid recipients.

The New York Times, Sept. 26, 2025 By Ann E. Marimow, Reporting from Washington The Supreme Court on Friday allowed the Trump administration to withhold \$4 billion in foreign aid that had been appropriated by Congress, in a preliminary test of President Trump's efforts to wrest the power of the purse from lawmakers.

In its brief order, the court's conservative majority allowed the president to cut the funding in part because it said his flexibility to engage in foreign affairs outweighed "the potential harm" faced by aid recipients. The justices cautioned that their decision, a temporary one while litigation continues, "should not be read as a final determination on the merits."

The three liberal justices dissented, saying the issue before the court was too consequential to have been dealt with on an emergency basis.

"The stakes are high: At issue is the allocation of power between the executive and Congress" over how government funds are spent, wrote Justice Elena Kagan, who was joined by Justices Sonia Sotomayor and Ketanji Brown Jackson.

In response to the Supreme Court order, lawyers for one of the challengers, the AIDS Vaccine Advocacy Coalition, said that the ruling allowed the administration to refuse to pay out billions it was required by law to spend.

"This result further erodes separation of powers principles that are fundamental to our constitutional order," Nicolas Sansone, a lawyer with the Public Citizen Litigation Group who represents the coalition, said in a statement. "It will also have a grave humanitarian impact on vulnerable communities throughout the world."...



U.S. States

No new digest content identified.

Tracking State Actions on Vaccine Policy and Access

Kaiser Family Foundation

Authors: <u>Jennifer Kates</u>, <u>Clea Bell</u>, <u>Josh Michaud</u>, <u>Elizabeth Williams</u>, and <u>Jennifer Tolbert</u>

Published: Sep 24, 2025

There is a complex interplay between the federal government and states regarding vaccine regulations, policy, and access. While states have the primary responsibility for enacting and enforcing laws to promote the health, safety, and general welfare of people in their jurisdictions, including, for example, instituting vaccine mandates, the federal government has significant authority to influence and alter vaccine policy through approvals and licensure, recommendations to the public and clinicians, funding, and legislative requirements that most insurers cover vaccines recommended by the Centers for Disease Control and Prevention (CDC) and its Advisory Committee on Immunization Practices (ACIP) at no-cost.

Moreover, states have generally relied on and <u>linked their own vaccine policies</u> to CDC/ACIP recommendations. However, with recent actions taken by Secretary of Health and Human Services, Robert F Kennedy, Jr., to curtail vaccine access – including narrowing both FDA-approval of COVID-19 vaccines and CDC's COVID-19 vaccine recommendations for the public, as well as changes to the pediatric vaccine schedule (see boxes 1-2) — many states have moved to maintain broader access (some states pre-emptively did so before the start of the Trump administration)...

As of September 22, 2025 (also see <u>Table 1</u>):

:: Twenty-six states have moved to allow pharmacists to administer COVID-19 vaccines without a prescription in an effort to maintain access as federal guidelines narrow.

Four states and DC have moved to do so beyond COVID-19 and include other vaccines, which could include those that may no longer be recommended by CDC/ACIP. Most of these states indicate that they are taking these actions to ensure COVID-19 vaccines remain widely available to all amid concerns about the narrowing of federal guidelines. Two states – North Carolina and Virginia – clarify that COVID-19 vaccines are available at pharmacies without a prescription (and allow individuals under the age of 65 to self-attest that they have an underlying condition in order to get vaccinated at a pharmacy without a prescription). Hawaii has joined a coalition of western states that has issued its own COVID-19 guidelines recommending universal vaccination for all those 6 months and older; it already authorizes pharmacists to administer vaccines to those ages 3 and older but has not issued an updated standing order for the COVID-19 vaccine. Among the remaining twenty-five states, while some may have general policies allowing pharmacists to administer recommended vaccines without a prescription, they have not made clear if this would permit them to do so for COVID-19 vaccines beyond federal limits.

:: Thirteen states have moved to require state-regulated health insurers to cover COVID-19 vaccines at no cost, including four that have done so for all vaccines recommended by the state.

In these states, regardless of changes to CDC/ACIP recommendations, which govern insurance coverage requirements for most insurers, state-regulated insurers will still need to cover these vaccines for free. In states that have not taken steps to require continued coverage of COVID-19 and other vaccines at no cost, if CDC adopts recent ACIP recommendations, individuals will no longer be guaranteed access to vaccines previously recommended by ACIP (though AHIP, the trade association for commercial insurers and other plans, has announced

that member insurers will continue to cover the vaccines with no cost sharing voluntarily, at least through 2026).

:: Twenty-two states specifically identify non-federal entities as sources for their vaccine recommendations, either in addition to or instead of CDC/ACIP.

In over half (13) of these states, the recommendations only apply to COVID-19 vaccines, while in nine states, the recommendations apply to all vaccines. Several states indicate that they will follow the recommendations of independent medical associations and professional groups (most commonly, AAP, AAFP, and ACOG) while others have established or are setting up their own state-led advisory bodies to develop vaccine recommendations. In addition, two interstate alliances have formed to develop shared recommendations and other resources, including the Northeast Public Health Collaborative and the West Coast Health Alliance, which together represent fourteen states (see Box 3). The West Coast Health Alliance recently issued its own vaccine recommendations for COVID-19, influenza and RSV for the 2025–26 respiratory virus season, which do not rely on ACIP.

:: There is a significant red-blue divide, with almost all states that have moved to maintain vaccine access despite federal changes having Democratic governors...

.....

U.S. Medical Societies, Health Organizations

American Academy of Pediatrics (AAP)

https://www.aap.org/en/news-room/news-releases-from-the-aap/ (Accessed 04 Sep 2025)

News

<u>Meta-Analysis: COVID-19 Vaccination During Pregnancy is Safe and Beneficial for Mother</u> and Infant

September 26, 2025

Vaccination is associated with better neonatal outcomes without added maternal risk, according to research presented during the American Academy of Pediatrics 2025 National Conference & Exhibition.

AAP Statement on White House Autism Announcement

September 22, 2025

Today's White House event on autism was filled with dangerous claims and misleading information that sends a confusing message to parents and expecting parents and does a disservice to autistic individuals.

American College of Physicians (ACP)

https://www.acponline.org/more-acp-news

(Accessed 04 Sep 2025)

ACP News

ACP issues statement calling for removal of Robert F. Kennedy Jr. as HHS Secretary 09/26/25

Infectious Diseases Society of America (IDSA)

https://www.idsociety.org/ (Accessed 04 Sep 2025) News

[No new digest content identified]

American Public Health Association (APHA)

https://www.apha.org/news-and-media/news-

releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc

(Accessed 04 Sep 2025)

News Releases

[No new digest content identified]

Society for Maternal-Fetal Medicine (SMFM)

https://www.smfm.org/

(Accessed 04 Sep 2025)

News

SMFM Response to Administration Announcement on Acetaminophen Use During Pregnancy and Autism

In response to today's White House press conference announcement, The Society for Maternal-Fetal Medicine (SMFM) reiterates its recommendation advising both physicians and patients that acetaminophen is an appropriate medication to treat pain and fever during pregnancy. Date posted - 09/22/2025

Massachusetts Public Health Alliance (MPHA)

https://mapublichealth.org/press-room/

(Accessed 04 Sep 2025)

Press Room

[No new digest content identified]

American Medical Association (AMA)

https://www.ama-assn.org/press-center

(Accessed 04 Sep 2025)

Press Center

[No new digest content identified]

American Academy of Family Physicians (AAFP)

https://www.aafp.org/news/media-center.html

(Accessed 04 Sep 2025)

Statements, Releases

Sep 22, 2025 —

AAFP: Linking Vaccines to Autism is Unproven and Dangerous

American Geriatrics Society (AGS)

https://www.americangeriatrics.org/media-center

(Accessed 04 Sep 2025)

Recent Press Releases

[No new digest content identified]

American Osteopathic Association (AOA)

https://osteopathic.org/news/

(Accessed 04 Sep 2025)

Latest News

Statements

AOA urges evidence-based and routine vaccination for patients

The American Osteopathic Association, representing nearly 200,000 osteopathic physicians and medical students...

09.23.25

National Medical Association (NMA)

https://nmanet.org/blog/ (Accessed 04 Sep 2025) Latest News

[No new digest content identified]

National Foundation for Infectious Diseases (NFID)

https://www.nfid.org/news-updates/ (Accessed 04 Sep 2025) News and Updates [No new digest content identified]

::::::::

Civil Society Organizations

Brookings

Reports, Events

<u>Tracking regulatory changes in the second Trump administration</u>

September 18, 2025

::::::

Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

::::::

Organization Announcements

Paul G. Allen Frontiers Group [27 Sep 2025]

https://alleninstitute.org/news-press/

Recent News

New study reveals rheumatoid arthritis begins long before symptoms, opening door to prevention

Sep 24, 2025

The seven-year study reveals early-warning signs that could help doctors catch the disease before it starts, potentially saving patients years of pain...

BMGF - Gates Foundation [27 Sep 2025]

https://www.gatesfoundation.org/ideas/media-center

Press Releases & Statements Press release Sep 24, 2025

<u>Gates Foundation Partners With Indian Manufacturer to Drive Down Cost of, Accelerate Access to Groundbreaking HIV Prevention Tool</u>

Press release Sep 22, 2025

With Millions of Children's Lives on the Line, Bill Gates Says Humanity Is at a Crossroads

CARB-X [27 Sep 2025]

https://carb-x.org/

News

No new digest content identified.

Chan Zuckerberg Initiative [27 Sep 2025]

https://chanzuckerberg.com/newsroom/

Newsroom

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [27 Sep 2025]

http://cepi.net/

CEPI News, Blog

No new digest content identified.

CIOMS - COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 27]

Sep 2025]

https://cioms.ch/

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [27 Sep 2025]

https://www.darpa.mil/news

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases initiative [27 Sep 2025]

https://dndi.org/press/press-releases/

Press Releases

Press releases 23 Sep 2025

Open-science approach delivers a promising pre-clinical candidate for broad-spectrum coronavirus antiviral

Duke Global Health Innovation Center [27 Sep 2025]

https://dukeghic.org/

News

No new digest content identified.

EDCTP [27 Sep 2025]

http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [27 Sep 2025]

http://www.vaccines.emory.edu/ Vaccine Center News No new digest content identified.

European Vaccine Initiative [27 Sep 2025]

http://www.euvaccine.eu/ Latest News, Events No new digest content identified.

Fondation Merieux [27 Sep 2025]

http://www.fondation-merieux.org/ Actualités No new digest content identified.

Gates Medical Research Institute [27 Sep 2025]

https://www.gatesmri.org/news

The Gates Medical Research Institute is a non-profit organization dedicated to the discovery, development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.

News: Articles and Publications No new digest content identified.

Gavi [to 27 Sep 2025] https://www.gavi.org/ News Releases No new digest content identified.

GE2P2 Global Foundation [27 Sep 2025]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

Digests

- :: Vaccines and Global Health: The Week in Review Current edition
- :: Informed Consent: A Monthly Review May 2025
- :: Public Consultations Watch :: Global Calls for Input/Public Comment 28 Aug 2025
- :: Genomics :: Governance, Ethics, Policy, Practice A Monthly Digest May 2025

GHIT Fund [27 Sep 2025]

https://www.ghitfund.org/newsroom/press

Press Releases

No new digest content identified.

Global Fund [to 27 Sep 2025]

https://www.theglobalfund.org/en/news/ News Releases

NEWS NEICASES

26 September 2025

Global Fund Applauds Switzerland's Pledge to the Eighth Replenishment

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) warmly applauds Switzerland's early pledge of CHF 64 million to the Eighth Replenishment.

25 September 2025

Global Fund Commends Portugal's Pledge to the Eighth Replenishment

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) commends Portugal's early pledge of €1.5 million to the Eighth Replenishment. The pledge was announced today in New York on the margins of the UN General Assembly.

24 September 2025

Global Fund Celebrates Private Sector Pledges Exceeding US\$1 Billion on Sidelines of UN General Assembly

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) announced private sector pledges totaling more than US\$1 billion over this last week, marking a major step forward in its Eighth Replenishment.

23 September 2025

<u>CIFF Commits Additional US\$50 Million to the Global Fund to Scale Up TB</u> Diagnosis

The Children's Investment Fund Foundation (CIFF) today announced a US\$50 million commitment to accelerate the introduction and rollout of innovative diagnostics for tuberculosis (TB). This marks the Foundation's first-ever investment in TB, building ...

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [27 Sep

20251

https://www.glopid-r.org/

News & Events

No new digest content identified.

Hilleman Laboratories [27 Sep 2025]

http://www.hilleman-labs.org/

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [27 Sep 2025]

https://www.hhmi.org/news

Press Room

Longevity May Be Passed From Parents to Children Through the Epigenome

New research led by HHMI Janelia Research Campus Senior Group Leader Meng Wang provides insights into how changes that help organisms deal with environmental stress are conferred to their offspring.

Sep 25, 2025

Human Immunome Project [nee Human Vaccines Project] [27 Sep 2025]

https://www.humanimmunomeproject.org/

News

Press Releases

<u>Human Immunome Project Announces Scientific Partner Network</u>

<u>Consortium to align scientific protocols to decipher the human immunome</u>

NEW YORK, September 25, 2025 – The Human Immunome Project (HIP) – a global NGO using artificial intelligence and big data to unlock the secrets of the human immune system in health and disease – today announced its Scientific Partner Network with nine founding institutional members on five continents.

IAVI [27 Sep 2025]
https://www.iavi.org/
Press Releases, Features
No new digest content identified.

INSERM [27 Sep 2025] https://www.inserm.fr/en/home/
Press Releases
No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

http://www.icmra.info/drupal/en/news Selected Statements, Press Releases, Research No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 27 Sep 2025]

https://www.ich.org/

News/Pubs/Press Releases [Selected]

24 September 2025

The ICH E2D(R1) Guideline reaches Step 4 of the ICH Process

The ICH E2D(R1) Guideline on "Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports" has reached Step 4 of the ICH Process on 15 September 2025 and has now entered the implementation phase at Step 5 of the ICH Process.

Ongoing Publ	ic Consultations	^
> M13B EWO	Bioequivalence for Immediate-Release Solid Oral Dosage Forms	
> Q1 EWG	Stability Testing of Drug Substances and Drug Products	
> M4Q(R2) E	WG Revision of M4Q(R1)	
> E21 EWG	Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials	
> Q3E EWG	Guideline for Extractables and Leachables	
∨ E20 EWG	Adaptive Designs for Clinical Trials	

https://www.ich.org/page/public-consultations

E20 EWG Adaptive Designs for Clinical Trials

The E20 EWG is working on the development of a new E20 Guideline on "Adaptive Clinical Trials" on the design, conduct, analysis, and interpretation of adaptive clinical trials that provides a transparent and harmonized set of principles for the regulatory review of these studies in a global drug development program. These principles should also provide the flexibility to evaluate / discuss innovative approaches to clinical trial design throughout the development process.

Following MC approval in June 2025 the E20 Guideline title was changed to "Adaptive Designs for Clinical Trials"

Rapporteur: Dr. Gregory Levin (FDA, United States) Regulatory Chair: Dr. Christian Roes (EC, Europe)

Date of Step 2b: 25 June 2025 Status: Step 3

Public consultation dates:

ANMAT, Argentina - Deadline for comments by 8 October 2025

EC, Europe - Deadline for comments by 30 November 2025

Health Canada, Canada - Deadline for comments by 25 September 025 MHRA,

UK - Deadline for comments by 30 November 2025

Swissmedic, Switzerland - Deadline for comments by 30 November 2025

TFDA, Chinese Taipei - Deadline for comments by 13 October 2025

ICRC [to 27 Sep 2025]

https://www.icrc.org/en/news

News

<u>Myanmar: Six months after the earthquake, access to clean water remains a lifeline for hard-hit communities</u>

News release 26-09-2025

IFFIm [27 Sep 2025] http://www.iffim.org/ Press Releases/Announcements No new digest content identified.

IFRC [to 27 Sep 2025]

http://media.ifrc.org/ifrc/news/press-releases/

Press releases

No new digest content identified.

IPPS - International Pandemic Preparedness Secretariat [27 Sep 2025]

https://ippsecretariat.org/news/

News

No new digest content identified.

Institut Pasteur [27 Sep 2025]

https://www.pasteur.fr/en/press-area

Press Documents

No new digest content identified.

ISC / International Science Council [to 27 Sep 2025]

https://council.science/current/

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

24 September 2025

Honouring science's principles in a troubled world

On 19 September 2025 in Tromsø, Norway, ISC President Sir Peter Gluckman delivered a lecture in honour of Professor Anne Husebekk. The lecture recognized her leadership in Norwegian academia, her commitment to polar science, and her service as ISC Vice-President and Chair of the Committee for Freedom and Responsibility in Science (CFRS).

Science is an organized system of knowledge – one based on observation and experimentation. Explanations can only be based only on causal reality, logic, and past observations. Explanations based on subjective and non-empirical considerations such as belief are excluded. Claims without the capacity for quality assessment by expert peers should not be considered part of science. Publication allows for replication and further investigation as well as ensuring that science can be a global public good. The processes of science are defined, not methodologically, but by iterative review and progressive modification of knowledge as new observations are made and incorporated.

International Union of Immunological Societies (IUIS)

https://iuis.org/ News/Events [Selected] No new digest content identified.

IVAC [27 Sep 2025]

https://www.ihsph.edu/research/centers-and-institutes/ivac/index.html

Updates; Events

No new digest content identified.

IVI [27 Sep 2025] http://www.ivi.int/ IVI News & Announcements No new digest content identified. https://centerforhealthsecurity.org/newsroom

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 27 Sep 2025]

http://www.msf.org/

Latest [Selected Announcements]

Gaza-Israel war

MSF forced to suspend activities amid intensified Israeli offensive in Gaza

Press Release 26 Sep 2025

Uzbekistan

MSF successfully concludes Nukus tuberculosis project in Uzbekistan

Project Update 24 Sep 2025

Yemen

Yemen witnesses worrying spike in acute watery diarrhoea cases

Press Release 23 Sep 2025

National Academy of Medicine - USA [to 27 Sep 2025]

https://nam.edu/programs/ News, Stories, Insights

Sep 25, 2025 *Insight*

Autism and Tylenol: Exploring the Evidence on Acetaminophen in Pregnancy

Margaret McCarthy discusses the genetics of autism, how to interpret associations in health studies, and why medical guidance matters.

Recently, the U.S. Food and Drug Administration (FDA) issued a <u>notice</u> that physicians should minimize patients' use of acetaminophen (the active ingredient in Tylenol) during pregnancy, citing a possible association with increased risk for autism and other neurological conditions in children. <u>Association is not the same as causation</u>, and the FDA stressed that a causal relationship has not been established. Currently, acetaminophen is <u>considered by OB-GYNs</u> to be a safe over-the-counter pain reliever and fever reducer for pregnant women.

We discussed the research behind the FDA's announcement with <u>Margaret McCarthy</u>, <u>PhD</u>, an NAM member and neuroscientist studying early brain development at the University of Maryland.

Sep 24, 2025 *Insight*

Shaping the Future of Sustainable Health Research

How the US and the UK national medical academies empowered future research leaders through a transatlantic partnership

Two years ago, Tom Solomon, International Vice President of the UK Academy of Medical Sciences, and Chris Hanley, Director of the Grand Challenge on Climate and Health at the US National Academy of Medicine, helped launch an ambitious transatlantic collaboration. Working alongside Program Leads Paula Williamson and Melissa Simon and project co-chairs Julia Wilson and Ying Goh, they helped to convene16 future research leaders from both countries to tackle a question with global stakes: how can health research be made more environmentally sustainable?

The effort culminated in <u>For People, For Planet: Improving the Environmental Sustainability of Health Research</u>, a policy report authored by the future research leaders, outlining steps to reduce the sector's environmental footprint—from laboratory design to procurement, funding incentives, and regulatory frameworks. It provides academic institutions, funders, regulators, and industry with a starting point for advancing human health without undermining planetary health.

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 27 Sep 2025]

https://www.nationalacademies.org/newsroom

News

No new digest content identified.

PATH [27 Sep 2025]

https://www.path.org/media-center/

Newsroom [Selected]

<u>CAF and PATH sign strategic alliance to strengthen health systems in Latin America</u>

September 23, 2025 by PATH

Partnership aims to advance health equity and digital transformation, with focus on maternal-child health, disease elimination, and emergency preparedness.

Sabin Vaccine Institute [27 Sep 2025]

https://www.sabin.org/press/ Latest News & Press Releases No new digest content identified.

UNAIDS [27 Sep 2025]

http://www.unaids.org/en News, Stories, Updates Press Statement 26 September 2025

<u>UNAIDS and Africa Centres for Disease Control and Prevention sign landmark agreement to strengthen community health systems and epidemic preparedness across Africa</u>

24 September 2025

<u>UNAIDS</u> welcomes the announcement of new deals to make new HIV prevention medicines available and...

23 September 2025

UN80 Secretary-General's report - UNAIDS statement

UNICEF [to 27 Sep 2025]

https://www.unicef.org/media/press-releases

Latest press releases, news notes and statements [Selected]

Press release 24 September 2025

DR Congo: UNICEF delivers vaccines and life-saving support as Ebola outbreak hits Kasai

KINSHASA, DR Congo, 24 September 2025, – Nearly 45,000 doses of the Ebola vaccine are on their way to Kasai province as UNICEF intensifies efforts alongside the government and partners to protect children and families from the latest outbreak in the Democratic Republic of the Congo (DRC). Since the outbreak was de...

Unitaid [27 Sep 2025]

https://unitaid.org/

Press Releases

<u>Unitaid, CHAI, and Wits RHI enter into a landmark agreement with Dr. Reddy's to make HIV prevention tool lenacapavir affordable in LMICs</u>

24 September 2025

Vaccine Equity Cooperative [nee Initiative] [27 Sep 2025]

https://vaccineequitycooperative.org/news/

News

No new digest content identified.

Vaccine Confidence Project [27 Sep 2025]

http://www.vaccineconfidence.org/ News, Research and Reports No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [27 Sep 2025]

http://www.chop.edu/centers-programs/vaccine-education-center

News

October 2025 – Hepatitis B Vaccine Birth Dose

In this video, Dr. Paul Offit talks about the history of hepatitis B vaccine recommendations and how the U.S. evolved to giving a birth dose of hepatitis B vaccine.

Wellcome Trust [27 Sep 2025]

https://wellcome.org/news/all News. Opinion, Reports No new digest content identified.

The Wistar Institute [to 27 Sep 2025]

https://www.wistar.org/news/press-releases
Press Releases
No new digest content identified.

World Bank [27 Sep 2025]

http://www.worldbank.org/en/news/all
All News [Selected]
No new digest content identified.

WFPHA: World Federation of Public Health Associations [27 Sep 2025]

https://www.wfpha.org/ Blog, Events No new digest content identified.

World Medical Association [WMA] [to 06 Sep 025]

https://www.wma.net/news-press/press-releases/

Press Releases

Invest in health workforce to win global fight against NCDs, says WHPA

25.09.2025

World Organisation for Animal Health [OIE] [27 Sep 2025]

https://www.oie.int/ Press Releases, Statements No new digest announcements identified.

::::::

ARM [Alliance for Regenerative Medicine] [27 Sep 2025]

https://alliancerm.org/press-releases/ Selected Press Releases No new digest announcements identified.

BIO [27 Sep 2025]

https://www.bio.org/press-releases

Press Releases

BIO Statement on Industry Tariffs

September 26, 2025

WASHINGTON, D.C. – John F. Crowley, President and CEO of the <u>Biotechnology Innovation</u> <u>Organization (BIO)</u> released the following statement on the potential for 100% tariffs on branded or patented medicines in the US:

"We share the Administration's goals for accelerating the onshoring of biomanufacturing in the United States. That is why the biopharmaceutical industry has announced more than \$350 billion in US biomanufacturing investments this year alone.

"The immediacy of punitive, 100% tariffs on innovative medicines for any company without 'shovels in the ground' would devastate our nation's small and mid-sized biotechnology companies. These 3,000+ companies are the heart and soul of America's vitally important biotechnology industry. Most of these companies do not have access to the significant capital needed to immediately establish manufacturing in the US. Due to the complexity and capital-intensive nature of biomanufacturing, the vast majority of these small-to mid-size biotech innovators rely on contract manufacturers to produce their medicines. These companies especially need time and stability in both the policy environment and capital markets to explore domestic manufacture of their often life-saving medicines, many of which are for rare and fatal diseases, often in children.

"Immediate tariffs in the biotechnology industry threaten America's health, national security, economic stability, and place as the world's leader in biotechnology. They would also devastate our industry and accelerate China's path to biotech dominance – which we cannot see happen."

DCVMN – Developing Country Vaccine Manufacturers Network [27 Sep 2025]

http://www.dcvmn.org/ News; Upcoming events

DCVMN Annual General Meeting 2025

October 29 - 31, 2025

Bali, Indonesia

ICBA – International Council of Biotechnology Associations [27 Sep 2025]

https://internationalbiotech.org/news/

News

No new digest announcements identified.

IFPMA [27 Sep 2025]

https://ifpma.org/

News, Statements [Selected] Statement 25 Sep 2025

<u>UN High-Level Meeting (HLM) on the Prevention and Control of Non-communicable</u>
<u>Diseases (NCDs) and the Promotion of Mental Health</u>

On 25 September 2025, IFPMA delivered a statement at the UN High-Level Meeting on NCDs and Mental Health in New York.

Read more

Statement 25 Sep 2025

<u>UN Political Declaration can accelerate action on non-communicable diseases (NCDs) and mental health</u>

On 25 September 2025, governments discussed a Political Declaration aimed at accelerating global efforts to prevent and control NCDs and promote mental health, including through a one-third reduction of premature mortality from these conditions by 2030. Commenting on the High-Level Meeting on NCDs and Mental Health, Dr David Reddy, Director General of IFPMA, said: "The...

Position paper 16 Sep 2025

Revitalizing the antibiotic pipeline by implementing new R&D pull incentives

With the 2024 UN High-Level Meeting on antimicrobial resistance (AMR) and its political declaration, together with the biennial AMR Ministerial Meeting, the world has set an ambitious agenda to tackle AMR. The next four years offer renewed political momentum to deliver progress ahead of the next UN High-Level Meeting on AMR in 2029. A central priority is creating the necessary policy frameworks that stimulate R&D investment. This brief identifies the key barriers to antibiotic R&D and the policy measures needed to address them. Sustainable, effective pull incentives are urgently required to ensure a reliable pipeline of new antibiotics for patients and health systems. We set out how these incentives should be designed and implemented, guided by a set of core principles to maximize their impact.

International Alliance of Patients' Organizations – IAPO [27 Sep 2025]

https://www.iapo.org.uk/news

Press and media [Selected]

World Patient Safety Day 2025 | Patient safety from the start!

Wednesday, 17 September 2025

Today marks the seventh annual <u>World Patient Safety Day</u>, and the International Alliance of Patients' Organisations (IAPO) stands with health advocates worldwide to address a pressing global challenge: ensuring the safety of our youngest and most vulnerable patients.

International Generic and Biosimilar Medicines Association [IGBA]

https://www.igbamedicines.org/

News

No new digest announcements identified.

PhRMA [27 Sep 2025]

http://www.phrma.org/

Press Releases

PhRMA Statement on Autism

WASHINGTON, D.C. (September 22, 2025) – Pharmaceutical Research and Manufacturers of America (PhRMA) Chief Medical Officer Dr. Michael Ybarra issued the following statement:

"Parents of children with autism want the best for their kids and ongoing research on the underlying causes and treatments are essential to provide the answers they deserve.

"Importantly, a vast body of scientific research has thoroughly debunked claims linking vaccines, their ingredients or the childhood immunization schedule to autism, and today's announcement does not change that."

Read more about decades of research finding no link between vaccines and autism.

::::::

Vaccines/Therapeutics/Medicines - Selected Developer/Manufacturer Announcements

We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.

AstraZeneca

<u>Press Releases</u> - No new digest announcements identified.

Bavarian Nordic

<u>Latest News</u> - No new digest announcements identified.

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified.

Biological E

News - No new digest announcements identified.

BioNTech

<u>Press Releases</u> - No new digest announcements identified.

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry.

CIGB

<u>Latest News</u> - No new digest announcements identified.

CinnaGen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

<u>News</u> - No new digest announcements identified.

CSL Sequirus

News Releases - No new digest announcements identified.

Curevac

<u>News</u> - No new digest announcements identified.

Dailchi Sankyo

Press Releases - No new digest announcements identified.

Gamaleya National Center/Sputnik

<u>Latest News and Events</u> - No new digest announcements identified [Last: 09 Nov 2020] <u>https://sputnikvaccine.com/</u> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

<u>Press releases for media</u> - No new digest announcements identified.

EuBiologics, S Korea

News - No new digest announcements identified.

HIPRA

Press releases

HIPRA receives European Commission approval for the commercialization of its COVID-19 vaccine adapted to the LP.8.1 variant

23-09-2025

IMBCAMS, China

Home - Website not responding at inquiry.

JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified.

Merck

News releases - No new digest announcements identified.

Nanogen

<u>News</u> - No new digest announcements identified.

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified.

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

https://rpharm-us.com/index.php

[No news or media page identified]

Sanofi Pasteur

Press Releases

September 24, 2025 Press Release:

<u>Sanofi commits an additional \$625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation</u>

- :: The fund will remain focused on Sanofi's key areas of immunology, rare diseases, neurology, and vaccines, backing earlier-stage innovation and emerging opportunities that support the company's long-term strategy
- :: Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies

Serum Institute

News & Announcements

Vidal Health and Serum Institute of India collaborate on HPV Vaccine access

- :: First-of-its-kind digital health programme on Vidal Health's platform will offer an end- to-end, convenient and cashless experience, making HPV vaccine more accessible.
- :: Collaboration is part of Vidal Health's efforts to provide preventive, digital-first healthcare. Mumbai/Pune, September 23, 2025: In a step towards preventive and digital-first healthcare, Vidal Health, India's second largest TPA service provider and Serum Institute of India (SII) Pvt. Ltd, part of Cyrus Poonawalla Group, the world's largest vaccine manufacturer, today announced a strategic collaboration to support national efforts in cervical cancer prevention and awareness.

Starting October 1, 2025, Vidal Health's platform will be the first-of-its-kind to offer an end-to-end, convenient and cashless experience for HPV vaccine – from digitally booking a doctor's appointment at a preferred location, to providing consent and receiving certification - all with zero paperwork. The fully managed health programme will provide complete support with timely dosage reminders, adherence monitoring...

Sinopharm/WIBPBIBP

News - No new digest announcements identified.

Sinovac

Press Releases - No new digest announcements identified.

SK Biosciences

Press Releases - No new digest announcements identified.

Takeda

Newsroom

20,000+ Takeda Employees Voted to Select Four New Global Corporate Social
Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 countries
September 24, 2025

Valneva

Press Releases - No new digest announcements identified.

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.] <u>Website</u> [No News/Announcements page identified]

::::::

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: <u>Journal Watch</u>
- :: Pre-Print Servers

::::::

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 16, 2025 Issue 3 https://www.tandfonline.com/toc/uabr21/current [Reviewed earlier]

AMA Journal of Ethics

Volume 27, Number 9: E629-711

https://journalofethics.ama-assn.org/issue/screening-children-structural-drivers-health

Screening Children for Structural Drivers of Health

Nearly half of all US children—40 million kids—were insured by Medicaid or children's health insurance programs in mid-2025. In 2024, the Centers for Medicare and Medicaid Services added a requirement that all hospitalized Medicaid patients be screened by a qualified clinician for structural drivers of health (SDoH). One justification for this requirement is that health outcomes, particularly for children of color, are widely documented as compromised by social, historical, and fiscal neglect of parental leave and other US policies that support children.

Regardless of whether screening for SDoH is federally required, pediatricians' understandings of factors that situate health outcomes for all US children, regardless of their insurance status, are key to caring well for children. Yet, despite the value of SDoH screening in improving US children's health outcomes, one problem is that even when such screening is feasible, it's not always clear which follow-up actions should be integrated into children's care plans, based on what screening reveals. This theme issue investigates clinical, ethical, and policy-level questions about how SDoH screening of children should be implemented and administered.

American Journal of Human Genetics

Sep 04, 2025 Volume 112 Issue 9 p1981-2250 https://www.cell.com/ajhg/current
This month in *The Journal*Paul W. Hook, Alyson B. Barnes

Parkinson disease (PD) is a genetically complex neurodegenerative disorder with more than ten million individuals affected worldwide. Although monogenic forms of PD have provided insights into the biological underpinnings of the disease, most PD appears to have a polygenic architecture. Interestingly, known risk variants only represent ~30% of the heritable component of the disease, and based on traits of similar heritability, there are expected to be many thousands of risk variants. To develop successful therapies, efforts to understand the genetic basis of PD need to be expansive and match the global nature of PD. [Reviewed earlier]

American Journal of Infection Control

September 2025 Volume 53 Issue 9 p919-1022 http://www.ajicjournal.org/current [Reviewed earlier]

American Journal of Preventive Medicine

September 2025 Volume 69 Issue 3 https://www.ajpmonline.org/current [Reviewed earlier]

American Journal of Public Health

October 2025 115(10) http://ajph.aphapublications.org/toc/ajph/current [Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 113 (2025): Issue 3 (Sep 2025) https://www.ajtmh.org/view/journals/tpmd/113/3/tpmd.113.issue-3.xml [Reviewed earlier]

Annals of Internal Medicine

September 2025 Volume 178, Issue 9 https://www.acpjournals.org/toc/aim/current [Reviewed earlier]

Artificial Intelligence - An International Journal

Volume 346 September 2025 https://www.sciencedirect.com/journal/artificial-intelligence/vol/346/suppl/C [New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation

http://resource-allocation.biomedcentral.com/ (Accessed 27 Sep 2025) [No new digest content identified]

BMC Health Services Research

http://www.biomedcentral.com/bmchealthservres/content (Accessed 27 Sep 2025 [No new digest content identified]

BMC Infectious Diseases

http://www.biomedcentral.com/bmcinfectdis/content

(Accessed 27 Sep 2025)

<u>Understanding the influence of religious and safety concerns on childhood measles and pertussis vaccination: a study conducted in Aceh, Indonesia, 2022</u>

Aceh, the westernmost province in Indonesia, was granted autonomous status, allowing the area to officially practice Sharia law, making the region religiously conservative. The province has the lowest measles ...

Authors: Annie A. Murphy, Rosaria Indah, Amanda Yufika, Ichsan Ichsan, Tita Menawati Liansyah,

Harapan Harapan, Daniel Birchok, Jason M. Poque, Fitdha Khairadini and Abram L. Wagner

Citation: BMC Infectious Diseases 2025 25:1140

Content type: Research Published on: 26 September 2025

<u>Pertussis resurgence in Iran: A systematic review and meta-analysis of seroimmunity and diagnostic evidence</u>

Pertussis, or whooping cough, remains a significant public health issue in Iran, despite high vaccination coverage. The incidence of pertussis has increased over the past two decades, attributed primarily to

Authors: Parvaneh Sadeghimoghadam, Reza Sattarpour, Maryam Noori, Nasim Sattarpour, Ali

Afkhaminia, Zeinab Sinaeifar, Amir Naddaf and Zahra Omidi

Citation: BMC Infectious Diseases 2025 25:1130

Content type: Systematic Review Published on: 26 September 2025

BMC Medical Ethics

http://www.biomedcentral.com/bmcmedethics/content

(Accessed 27 Sep 2025)

Interventions to promote medical research integrity: a scoping review

This study reviewed the current status of interventions for medical research integrity. The forms and methods of interventions, the timing and duration of interventions, outcome indicators, and evaluation meth...

Authors: Sihui Liu, Yang Yang and Miqi Li Citation: *BMC Medical Ethics* 2025 26:117

Content type: Research Published on: 24 September 2025

BMC Medicine

http://www.biomedcentral.com/bmcmed/content (Accessed 27 Sep 2025) No new digest content identified]

BMC Pregnancy and Childbirth

http://www.biomedcentral.com/bmcpregnancychildbirth/content (Accessed 27 Sep 2025)

No new digest content identified]

BMC Public Health

http://bmcpublichealth.biomedcentral.com/articles

(Accessed 27 Sep 2025)

Variation in COVID-19 vaccination and adverse outcomes: a state of Georgia case study

Differences in COVID-19 vaccine coverage, deaths, and hospitalizations across racial and ethnic groups have been documented in the United States. Evaluating these patterns at a smaller geographical scale while...

Authors: Akane B. Fujimoto, Pinar Keskinocak and Dima Nazzal

Citation: BMC Public Health 2025 25:3128

Content type: Research Published on: 25 September 2025

BMC Research Notes

http://www.biomedcentral.com/bmcresnotes/content (Accessed 27 Sep 2025) [No new digest content identified]

BMJ Evidence-Based Medicine

August 2025 - Volume 30 - 4 https://ebm.bmj.com/content/30/4 [Reviewed earlier]

BMJ Global Health

August 2025 - Volume 10 - Suppl 5 https://gh.bmj.com/content/10/Suppl 5 [Reviewed earlier]

Bulletin of the Atomic Scientists

DIGITAL MAGAZINE - September 2025 https://thebulletin.org/magazine/2025-09/#post-heading [Reviewed earlier]

Bulletin of the World Health Organization

Volume 103, Number 9, September 2025, 517 https://www.who.int/publications/journals/bulletin/ [Reviewed earlier]

Cell

Sep 04, 2025 Volume 188 Issue 18 p4811-5120 https://www.cell.com/cell/current [Reviewed earlier]

Cell and Gene Therapy Insights

May 2025 Issue Volume 11 Issue 4

https://www.insights.bio/cell-and-gene-therapy-insights/journal/250/volume-11-issue-4

[Reviewed earlier]

Child Care, Health and Development

Volume 51, Issue 5 September 2025 https://onlinelibrary.wiley.com/toc/13652214/current [Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 118, Issue 3 Pages: 521-745 September 2025 https://ascpt.onlinelibrary.wiley.com/toc/15326535/current [Reviewed earlier]

Clinical Therapeutics

September 2025 Volume 47 Issue 9 p663-826 http://www.clinicaltherapeutics.com/current [Reviewed earlier]

Clinical Trials

Volume 22 Issue 4, August 2025 https://journals.sagepub.com/toc/ctja/22/4 [Reviewed earlier]

Conflict and Health

http://www.conflictandhealth.com/ [Accessed 27 Sep 2025] [No new digest content identified]

Contemporary Clinical Trials

Volume 156 September 2025 https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/156/suppl/C [Reviewed earlier]

The CRISPR Journal

Volume 8, Issue 4 / August 2025 https://www.liebertpub.com/toc/crispr/8/4 [Reviewed earlier]

Current Genetic Medicine Reports

Volume 13, Issue 1 December 2025 https://link.springer.com/journal/40142/volumes-and-issues/13-1 [Reviewed earlier]

Current Medical Research and Opinion

Volume 41, Issue 3 2025 https://www.tandfonline.com/toc/icmo20/current [Reviewed earlier]

Current Opinion in Infectious Diseases

October 2025 - Volume 38 - Issue 5 https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx PAEDIATRIC AND NEONATAL INFECTIONS [Reviewed earlier]

Current Protocols in Human Genetics

https://currentprotocols.onlinelibrary.wiley.com/journal/19348258 [Accessed 27 Sep 2025] [No new digest content identified]

Cytotherapy

September 2025 Volume 27 Issue 9 p1031-1150 https://www.isct-cytotherapy.org/current [Reviewed earlier]

Developing World Bioethics

Volume 25, Issue 3 Pages: 165-252 September 2025 https://onlinelibrary.wiley.com/toc/14718847/current [Reviewed earlier]

Development in Practice

Volume 35, Issue 5, 2025 https://www.tandfonline.com/toc/cdip20/35/5?nav=tocList [Reviewed earlier]

Development Policy Review

Volume 43, Issue 5 September 2025 https://www.tandfonline.com/toc/cdip20/35/5?nav=tocList [Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 19 - 2025

 $\underline{https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-\underline{issue}$

[Reviewed earlier]

Disasters

Volume 49, Issue 4 October 2025 https://onlinelibrary.wiley.com/toc/14677717/current

Future of humanitarian and development aid

[Reviewed earlier]

eBioMedicine

Volume 119 September 2025

https://www.sciencedirect.com/journal/ebiomedicine/vol/119/suppl/C

Discussion Open access

Clade I mpox vaccination: strategies for deployment and evaluation

Caitlin Pley, Jasmina Panovska-Griffiths, Robert Hinch, Chris Wymant, ... Christophe Fraser Article 105890

AITICIE 103030

EMBO Reports

Volume 26 Issue 17 9 September 2025 https://www.embopress.org/toc/14693178/current [Reviewed earlier]

Emerging Infectious Diseases

Volume 31, Number 9—September 2025 http://wwwnc.cdc.gov/eid/ [Reviewed earlier]

Epidemics

Volume 52 September 2025 https://www.sciencedirect.com/journal/epidemics/vol/52/suppl/C [Reviewed earlier]

Epidemiology and Infection

Volume 153 - 2025

https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue [Reviewed earlier]

Ethics & Human Research

Volume 47, Issue 4 Pages: 1-17 July–August 2025 https://onlinelibrary.wiley.com/toc/25782363/current

Sharing aggregate results :: Consent and health data

[Reviewed earlier]

Ethics & International Affairs

Volume 39 - Issue 1 - Spring 2025 https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue [Reviewed earlier]

Ethics, Medicine and Public Health

Volume 32 2024

https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc [Reviewed earlier]

The European Journal of Public Health

Volume 35, Issue 4, August 2025 https://academic.oup.com/eurpub/issue/35/4 [Reviewed earlier]

Expert Review of Vaccines

Volume 24, 2025 Issue 1 https://www.tandfonline.com/toc/ierv20/current [Reviewed earlier]

Foreign Affairs

July/August 2025 Volume 104, Number 4 https://www.foreignaffairs.com/issues/2025/104/4 [Reviewed earlier]

Forum for Development Studies

Volume 52, 2025 - Issue 2 http://www.tandfonline.com/toc/sfds20/current

The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities [Reviewed earlier]

Frontiers in Genetics

https://www.frontiersin.org/journals/genetics [Accessed 27 Sep 2025] [No new digest content identified]

Frontiers in Genome Editing

https://www.frontiersin.org/journals/genome-editing [Accessed 27 Sep 2025] [No new digest content identified]

Frontiers in Medicine

https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463 [Accessed 27 Sep 2025] [No new digest content identified]

Gene Therapy - Nature

Volume 32 Issue 4, July 2025 https://www.nature.com/gt/volumes/32/issues/4 [Reviewed earlier]

Genetics in Medicines

Volume 27, Issue 6 June 2025 https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/65 [Reviewed earlier]

Genome Medicine

https://genomemedicine.biomedcentral.com/articles [Accessed 27 Sep 2025] [No new digest content identified]

Global Health Action

Volume 18, Issue 1 (2025) https://www.tandfonline.com/toc/zgha20/current?nav=tocList [Reviewed earlier]

Global Health: Science and Practice (GHSP)

August 2025 | Volume 13 | Number 1 http://www.ghspjournal.org/content/current [Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

https://www.loc.gov/collections/global-legal-monitor/
https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+l
aw+library+of+congress%29&sb=date_desc
[Accessed 27 Sep 2025]
[No new digest content identified]

Global Public Health

Volume 20, Issue 1 (2025) http://www.tandfonline.com/toc/rgph20/current [Reviewed earlier]

Globalization and Health

http://www.globalizationandhealth.com/ [Accessed 27 Sep 2025] [No new digest content identified]

Health and Human Rights

Volume 27, Issue 1, June 2025 https://www.hhrjournal.org/volume-27-issue-1-june-2025/ SPECIAL SECTION FIGHT FOR RIGHTS VIEWPOINT SERIES

Health Economics, Policy and Law

Volume 20 - Issue 3 - July 2025

https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue [Reviewed earlier]

Health Policy and Planning

Volume 40, Issue 8, September 2025

https://academic.oup.com/heapol/issue/40/8

Review

Cervical cancer prevention and control in Nigeria: mapping and review of policies

Elvis Anyaehiechukwu Okolie and others

Health Policy and Planning, Volume 40, Issue 8, September 2025, Pages 931–942,

https://doi.org/10.1093/heapol/czaf049

Health Research Policy and Systems

http://www.health-policy-systems.com/content

[Accessed 27 Sep 2025]

[No new digest content identified]

Human Gene Therapy

Volume 36, Issue 15-16 / August 2025

https://www.liebertpub.com/toc/hum/36/15-16

Special Issue on Gene Therapy for Diseases of the Respiratory System

[New issue; No digest content identified]

Humanitarian Practice Network

https://odihpn.org/ [Accessed 27 Sep 2025]

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 21 Issue 1, 2025

https://www.tandfonline.com/toc/khvi20/21/1?nav=tocList

Selected Content

[Reviewed earlier]

Immunity

Sep 09, 2025 Volume 58 Issue 9 p2139-2354

https://www.cell.com/immunity/current

[Reviewed earlier]

Infectious Agents and Cancer

http://www.infectagentscancer.com/

[Accessed 27 Sep 2025]

Infectious Diseases of Poverty

http://www.idpjournal.com/content]
[Accessed 27 Sep 2025]
[No new digest content identified]

International Health

Volume 17, Issue 5, September 2025 https://academic.oup.com/inthealth/issue/17/5 Original Articles

<u>Ethical issues surrounding the implementation of long-acting injectable antiretroviral</u> therapy in sub-Saharan Africa

Deborah Ekusai-Sebatta and others International Health, Volume 17, Issue 5, September 2025, Pages 695–700, https://doi.org/10.1093/inthealth/ihaf016

International Human Rights Law Review

Volume 14 (2025): Issue 1 (Jun 2025) https://brill.com/view/journals/hrlr/14/1/hrlr.14.issue-1.xml [Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 12 No. 9 (2025): September 2025 https://www.ijcmph.com/index.php/ijcmph/issue/view/128 [Reviewed earlier]

International Journal of Epidemiology

Volume 54, Issue 3, June 2025 https://academic.oup.com/ije/issue/54/3 [Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 18 Issue 2 2025 https://www.emerald.com/ijhrh/issue/18/3 Table of contents [Reviewed earlier]

JAMA

September 23/30, 2025, Vol 334, No. 12, Pages 1039-1124 https://jamanetwork.com/journals/jama/currentissue [New issue; No digest content identified]

JAMA Health Forum

September 2025, Vol 6, No. 9 https://jamanetwork.com/journals/jama-health-forum/issue [New issue; No digest content identified]

JAMA Pediatrics

September 2025, Vol 179, No. 9, Pages 935-1048 https://jamanetwork.com/journals/jamapediatrics/currentissue [Reviewed earlier]

JBI Evidence Synthesis

August 2025 - Volume 23 - Issue 8 https://journals.lww.com/jbisrir/Pages/currenttoc.aspx [Reviewed earlier]

Journal of Adolescent Health

September 2025 Volume 77 Issue 3 p339-586 https://www.jahonline.org/current [Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 83 (2025) https://www.jair.org/index.php/jair [Reviewed earlier]

Journal of Bioethical Inquiry

Volume 22, Issue 1 March 2025 https://link.springer.com/journal/11673/volumes-and-issues/22-1 [Reviewed earlier]

Journal of Community Health

Volume 50, Issue 3 June 2025 https://link.springer.com/journal/10900/volumes-and-issues/50-3 [Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 8 No. 01 (2025)

https://www.cmro.in/index.php/jcmro/issue/view/91

[Reviewed earlier]

Journal of Development Economics

Volume 176 September 2025

https://www.sciencedirect.com/journal/journal-of-development-economics/vol/176/suppl/C [Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 20 Issue 3, July 2025 http://journals.sagepub.com/toc/jre/current [Reviewed earlier]

Journal of Epidemiology & Community Health

September 2025 - Volume 79 - 9 https://jech.bmj.com/content/79/9 [Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 18, Issue 2 June 2025 https://onlinelibrary.wiley.com/toc/17565391/current [Reviewed earlier]

Journal of Global Ethics

Volume 21, Issue 2 (2025) http://www.tandfonline.com/toc/rjge20/current [Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 36, Number 2, May 2025 https://muse.jhu.edu/issue/54734 Table of Contents [Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 27, Issue 4 August 2025 https://link.springer.com/journal/10903/volumes-and-issues/27-4 [Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 23, Issue 3 (2025) https://www.tandfonline.com/toc/wimm20/current [Reviewed earlier]

Journal of International Development

Volume 37, Issue 6 Pages: 1-1404 August 2025 https://onlinelibrary.wiley.com/toc/10991328/current [Reviewed earlier]

Journal of Medical Ethics

September 2025 - Volume 51 - 9 http://jme.bmj.com/content/current [Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 12, Issue 3 (2025) https://institutionalrepository.aah.org/jpcrr/ [Reviewed earlier]

The Journal of Pediatrics

Volume 284 September 2025 https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/284/suppl/C [Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 284 September 2025
https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/284/suppl/C
[Reviewed earlier]

https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList
[Reviewed earlier]

Journal of Public Health Management & Practice

July/August 2025 - Volume 31 - Issue 4 https://journals.lww.com/jphmp/pages/currenttoc.aspx [Reviewed earlier]

Journal of Public Health Policy

Volume 46, Issue 3 September 2025 https://link.springer.com/journal/41271/volumes-and-issues/46-3 Editorial 05 June 2025

The Pandemic Agreement: a strategy for global emergency response collaboration Elena N. Naumova

Journal of the Royal Society – Interface

September 2025 Volume 22 Issue 230 https://royalsocietypublishing.org/toc/rsif/current [Reviewed earlier]

Journal of Travel Medicine

Volume 32, Issue 5, July 2025 https://academic.oup.com/jtm/issue [Reviewed earlier]

Journal of Virology

Volume 99 • Number 6 • June 2025 http://jvi.asm.org/content/current [Reviewed earlier]

The Lancet

Sep 27, 2025 Volume 406 Number 10510 p1313-1442 https://www.thelancet.com/journals/lancet/issue/current Comment

Offline: Research integrity—a challenge not a crisis
Richard Horton

The Lancet Child & Adolescent Health

Oct 2025 Volume 9 Number 10 p685-752 https://www.thelancet.com/journals/lanchi/issue/current [Reviewed earlier]

Lancet Digital Health

Aug 2025 Volume 7 Number 8 https://www.thelancet.com/journals/landig/issue/current [Reviewed earlier]

Lancet Global Health

Sep 2025 Volume 13 Number 9 e1489-e1653 https://www.thelancet.com/journals/langlo/issue/current [Reviewed earlier]

Lancet Infectious Diseases

Sep 2025 Volume 25 Number 9 p947-1054, e491-e541 https://www.thelancet.com/journals/laninf/issue/current [Reviewed earlier]

Lancet Public Health

Sep 2025 Volume 10 Number 9 e722-e803 https://www.thelancet.com/journals/lanpub/issue/current [Reviewed earlier]

Lancet Respiratory Medicine

Sep 2025 Volume 13 Number 9 p769-856, e45-e52 https://www.thelancet.com/journals/lanres/issue/current [Reviewed earlier]

Maternal and Child Health Journal

Volume 29, Issue 6 June 2025 https://link.springer.com/journal/10995/volumes-and-issues/29-6 [Reviewed earlier]

Medical Decision Making (MDM)

Volume 45 Issue 7, October 2025 http://mdm.sagepub.com/content/current [Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy Volume 103, Issue 3 Pages: 639-939 September 2025 https://onlinelibrary.wiley.com/toc/14680009/current [Reviewed earlier]

Molecular Therapy

Sep 03, 2025 Volume 33 Issue 9 p4009-4656 https://www.cell.com/molecular-therapy/current [Reviewed earlier]

Nature

Volume 645 Issue 8082, 25 September 2025 https://www.nature.com/nature/volumes/645/issues/8081

The future of universities

Universities have been the cornerstone of higher education for centuries, but since the end of the Second World War, their role has changed significantly. More recently, technological innovations such as artificial intelligence have increased pressure on these institutions like never before, posing fundamental questions about what education is for, how it should be delivered and how it should be funded. This week, <u>in a special issue</u>, *Nature* probes the challenges faced by higher education — drawing on examples from across the world to assess how the sector can adapt to survive.

Editorial 24 Sept 2025

<u>Universities are — and must continue to be — a force for good</u>

From funding squeezes to political attacks, higher education is in trouble in many parts of the world. Fresh ideas will allow the sector to thrive and deliver value for society.

World View 24 Sept 2025

Universities under fire must harness more of the financial value they create

Attacks on US academic institutions miss the point that they generate wealth for society. Tapping even some of that could keep innovation going. Yasheng Huang

World View 24 Sept 2025

How can universities train the skilled workers of tomorrow?

The high cost of running educational laboratories is hindering industrial progress. An innovative path forwards must be charted.

Roseanne Warren

Comment 24 Sept 2025

How universities came to be — and why they are in trouble now

What and who universities are for has changed considerably since the Second World War, leaving long-standing institutions ill-equipped to cope with current financial and political challenges. Philip G. Altbach

Comment 24 Sept 2025

Universities must move with the times: how six scholars tackle AI, mental health and more

Societies are evolving, and so must higher education. Researchers describe initiatives that can help to create stimulating and nurturing environments fit for today's learning landscape. Ya-Oin Zhang, Ramesh Jagannathan, Sibonokuhle Ndlovu

Nature Biotechnology

Volume 43 Issue 9, September 2025 https://www.nature.com/nbt/volumes/43/issues/9 *Editorial* 04 Sept 2025

Advancing antivirals

Funding and public support for vaccines in the United States is at an all-time low. Promising research is resulting in effective antivirals, but they should not take the place of vaccines.

Comment 19 Aug 2025

Redefining druggable targets with artificial intelligence

A vast landscape of 'undruggable' cancer targets remains beyond the reach of conventional therapeutic agents. Recent advances in artificial intelligence (AI), however, are challenging this paradigm. Synthesizing insights from a Cancer Moonshot workshop, we argue that systemically addressing the undruggable target space with AI requires a new conceptual framework. We highlight the failure of current target taxonomies and the need for benchmarking datasets, and re-evaluate clinical validation for novel AI-driven modalities.

Karen Akinsanya, Mohammed AlQuraishi, Olivier Elemento

Nature Communications

https://www.nature.com/subjects/health-sciences/ncomms (Accessed 27 Sep 2025) [Reviewed earlier]

Nature Genetics

Volume 57 Issue 9, September 2025 https://www.nature.com/ng/volumes/57/issues/9 [Reviewed earlier]

Nature Human Behaviour

Volume 9 Issue 8, August 2025 https://www.nature.com/nathumbehav/volumes/9/issues/8 [Reviewed earlier]

Nature Medicine

Volume 31 Issue 9, September 2025 https://www.nature.com/nm/volumes/31/issues/9

World View 18 Aug 2025

For science to thrive we must protect scientists from harassment

Throughout my academic career, I have been a supporter of freedom of thought and expression. Peter Singer

Article Open Access 27 Aug 2025

Global distribution of research efforts, disease burden, and impact of US public funding withdrawal

Leo Schmallenbach, Maximilian Bley, Marc J. Lerchenmueller Abstract

Evaluating whether research aligns with the global burden of disease is essential for equitable and effective scientific progress and improvement of human health. Without systematic evaluation of this alignment, science cannot respond to shifting health needs. Here we analyzed the distribution between research and disease, linking 8.6 million disease-specific publications to two decades of global disease burden data using a triangulated large language model approach. We find that since 1999, research and disease burden have seemingly become much more aligned; however, this is mainly because of regional declines in communicable disease burden, whereas the noncommunicable disease burden has increased and globalized. Meanwhile, research effort has not changed to match changes in disease burden. Our simulations suggest that without intentional alignment, the research—disease divergence will probably widen by a third over the next two decades, and be substantially accelerated by the reduction of US public funding for international research. Aligning research with health needs will require strategic investments, improved global coordination, open science policies and stronger, more equitable international partnerships to build resilience in a fragile research ecosystem.

Nature Reviews Drug Discovery

Volume 24 Issue 9, September 2025

https://www.nature.com/nrd/volumes/24/issues/9

Comment 25 Jun 2025

Generative AI: a generation-defining shift for biopharma regulatory affairs

As biopharmaceutical companies face mounting pressure to accelerate development timelines and improve the speed and quality of regulatory submissions, many are actively exploring the potential of generative artificial intelligence (GenAI) to transform how regulatory work gets done. This article examines how leading organizations are beginning to apply GenAI to automate content creation, analyse complex data and streamline core regulatory activities — and the critical success factors for driving adoption at scale.

Jon Williams, Donna Boyce, Myrto Lee

Nature Reviews Genetics

Volume 26 Issue 9, September 2025 https://www.nature.com/nrg/volumes/26/issues/9 [New issue; No digest content identified]

Nature Reviews Immunology

Volume 25 Issue 8, August 2025 https://www.nature.com/nri/volumes/25/issues/8 [Reviewed earlier] Volume 393 No. 12 September 25, 2025 https://www.nejm.org/toc/nejm/medical-journal Perspective

<u>From Health to Wealth — Reframing Global Aid through the Gates Foundation's Final Chapter</u>

S. Phillips

In the Gates Foundation's final chapter, it is doubling down on its wager that health can engender prosperity. That proposition must now contend with the mixed macroeconomic evidence.

NEJM Evidence

Volume 4 No. 9 September 2025 https://evidence.nejm.org/toc/evid/current

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

https://www.nature.com/npjvaccines/ [Accessed 27 Sep 2025] [No new digest content identified]

Pediatrics

Volume 156, Issue 3 September 2025 https://publications.aap.org/pediatrics/issue/156/3 [Reviewed earlier]

PharmacoEconomics

Volume 43, Issue 8 August 2025 https://link.springer.com/journal/40273/volumes-and-issues/43-8 [Reviewed earlier]

PLoS Biology

https://journals.plos.org/plosbiology/ (Accessed 27 Sep 2025) [No new digest content identified]

PLoS Genetics

https://journals.plos.org/plosgenetics/ (Accessed 27 Sep 2025) [No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2 021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60 (Accessed 27 Sep 2025)

[No new digest content identified]

PLoS Medicine

https://journals.plos.org/plosmedicine/ (Accessed 27 Sep 2025) [No new digest content identified]

PLoS Neglected Tropical Diseases

http://www.plosntds.org/ (Accessed 27 Sep 2025) [No new digest content identified]

PLoS One

http://www.plosone.org/ [Accessed 27 Sep 2025] [No new digest content identified]

PLoS Pathogens

http://journals.plos.org/plospathoge ns/ [Accessed 27 Sep 2025] [No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

September 23, 2025 vol. 122 no. 38 https://www.pnas.org/toc/pnas/122/38 [New issue; No digest content identified]

PNAS Nexus

Volume 4, Issue 8, August 2025 https://academic.oup.com/pnasnexus/issue/4/8 [Reviewed earlier]

Prehospital & Disaster Medicine

Volume 40 - Issue 3 - June 2025 https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue [Reviewed earlier]

Preventive Medicine

Volume 198 September 2025

https://www.sciencedirect.com/journal/preventive-medicine/vol/198/suppl/C

Research article Open access

Social determinants of health and COVID-19 vaccination: An individual participant data meta-analysis of adult Latino participants

Stephanie De Anda, Elizabeth L. Budd, Pimwadee Chaovalit, Amy H. Vu, ... David S. DeGarmo

Proceedings of the Royal Society B

September 2025 Volume 292 Issue 2055

https://royalsocietypublishing.org/toc/rspb/current

Special feature: The other 1%: Showcasing science and scientists from the Global South and indigenous communities

[Reviewed earlier]

Public Health

Volume 245 August 2025 https://www.sciencedirect.com/journal/public-health/vol/245/suppl/C [Reviewed earlier]

Public Health Ethics

Volume 18, Issue 2, July 2025 http://phe.oxfordjournals.org/content/current [Reviewed earlier]

Public Health Genomics

2025, Vol. 28, No. 1 https://karger.com/phg/issue/28/1 [Reviewed earlier]

Public Health Reports

Volume 140 Issue 2-3, March-April/May-June 2025 https://journals.sagepub.com/toc/phrg/140/2-3 [Reviewed earlier]

Qualitative Health Research

Volume 35 Issue 12, October 2025 https://journals.sagepub.com/toc/QHR/current [Reviewed earlier]

Research Ethics

Volume 21 Issue 3, July 2025 http://journals.sagepub.com/toc/reab/current [Reviewed earlier]

Reproductive Health

http://www.reproductive-health-journal.com/content [Accessed 27 Sep 2025] [No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

https://www.paho.org/journal/en Latest Articles [No new digest content identified]

Risk Analysis

Volume 45, Issue 7 Pages: 1597-2068 July 2025 https://onlinelibrary.wiley.com/toc/15396924/current [Reviewed earlier]

Risk Management and Healthcare Policy

https://www.dovepress.com/risk-management-and-healthcare-policy-archive56 [Accessed 27 Sep 2025]
[No new digest content identified]

Royal Society Open Science

September 2025 Volume 12 Issue 9 https://royalsocietypublishing.org/toc/rsos/current [Reviewed earlier]

Science

Volume 389| Issue 6767| 25 Sep 2025 https://www.science.org/toc/science/current Feature

NSF held captive

BY Jeffrey Mervis

25 Sep 2025: 1286-1290

Trump directives have undermined a 75-year history of independence and threaten the agency's vaunted track record for excellence

Policy Articles

What if NIH had been 40% smaller?

BY Pierre Azoulay, Matthew Clancy, Danielle Li, Bhaven N. Sampat

25 Sep 2025: 1303-1305

Replaying history with less NIH funding shows widespread impacts on drug-linked research

In Depth

Ethicists flirt with AI for reviewing human research

BY Celina Zhao 25 Sep 2025: 1281-1282

Large language models could help reduce backlog of study proposals, but critics are wary of entrusting ethics to machines

Science and Engineering Ethics

Volume 31, Issue 4 August 2025 https://link.springer.com/journal/11948/volumes-and-issues/31-4

[Reviewed earlier]

Science Translational Medicine

Volume 17| Issue 817| 24 Sep 2025 https://www.science.org/toc/stm/current [New issue; No digest content identified]

Scientific Reports

https://www.nature.com/srep/articles?type=article [Accessed 27 Sep 2025] [No new digest content identified]

Social Science & Medicine

Volume 380 September 2025 https://www.sciencedirect.com/journal/social-science-and-medicine/vol/380/suppl/C [Reviewed earlier]

Systematic Reviews

https://systematicreviewsjournal.biomedcentral.com/articles [Accessed 27 Sep 2025] [No new digest content identified]

Theoretical Medicine and Bioethics

Volume 46, Issue 5 October 2025 https://link.springer.com/journal/11017/volumes-and-issues/46-5 [New issue; No digest content identified]

Travel Medicine and Infectious Diseases

Volume 66 July–August 2025 https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/66/suppl/C [Reviewed earlier]

Tropical Medicine & International Health

Volume 30, Issue 9 Pages: 865-1022 September 2025 https://onlinelibrary.wiley.com/toc/13653156/current [Reviewed earlier]

Vaccine

Volume 63 17 September 2025 https://www.sciencedirect.com/journal/vaccine/vol/63/suppl/C [Reviewed earlier]

Vaccines

https://www.mdpi.com/journal/vaccines

[Accessed 27 Sep 2025] Open Access Article

<u>Human Papillomavirus Vaccination Coverage Estimates Among the Primary Target Cohort</u> (9–14-Year-Old Girls) in the World (2010–2024)

by Irena Ilic and Milena Ilic

Vaccines 2025, 13(10), 1010; https://doi.org/10.3390/vaccines13101010 (registering DOI) - 27 Sep 2025

Abstract

Background/Objectives: Monitoring human papillomavirus (HPV) vaccine coverage worldwide can provide valuable insight into cervical cancer prevention. The aim of this manuscript was to assess the HPV vaccination coverage among the primary target cohort (9–14-year-old girls) in the world from 2010 to 2024. [...]

Open Access Systematic Review

<u>Multilevel Interventions Aimed at Improving HPV Immunization Coverage: A Systematic Review and Meta-Analysis</u>

by Irena Ilic, Vladimir Jakovljevic, Mario Gajdacs, Edit Paulik and Milena Ilic Vaccines 2025, 13(10), 1001; https://doi.org/10.3390/vaccines13101001 - 25 Sep 2025 Abstract

Background/Objectives: Human papillomavirus (HPV)-attributable cancers are a major public health problem worldwide. However, HPV vaccination rates vary significantly and are often not optimal. This study aimed to assess the effects of multilevel interventions on improving HPV vaccination. Methods: A systematic literature review and [...

Open Access Article

<u>Multilevel Analysis of Zero-Dose Children in Sub-Saharan Africa: A Three Delays Model Study</u>

by Charles S. Wiysonge, Muhammed M. B. Uthman, Duduzile Ndwandwe and Olalekan A. Uthman Vaccines 2025, 13(9), 987; https://doi.org/10.3390/vaccines13090987 - 21 Sep 2025

**Abstract*

Background: Zero-dose children represent a critical challenge for achieving universal immunization coverage in sub-Saharan Africa. This study applies the Three Delays Model to examine multilevel factors associated with zero-dose children. Methods: We analyzed data from 30,500 children aged 12–23 months across 28 sub-Saharan [.

Value in Health

September 2025 Volume 28 Issue 9 p1305-1460 https://www.valueinhealthjournal.com/current [Reviewed earlier]

World Development

Volume 193 September 2025 https://www.sciencedirect.com/journal/world-development/vol/193/suppl/C [Reviewed earlier]

::::::

- :: <u>WHO</u>
- :: Organization Announcements
- :: <u>Journal Watch</u>
- :: Pre-Print Servers

::::::

Pre-Print Servers

arxiv

https://arxiv.org/

[Accessed 27 Sep 2025]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

arXiv:2509.19088 [pdf, other]

A Mega-Study of Digital Twins Reveals Strengths, Weaknesses and Opportunities for Further Improvement

<u>Tiany Peng, George Gui, Daniel J. Merlau, Grace Jiarui Fan, Malek Ben Sliman, Melanie Brucks, Eric J. Johnson, Vicki Morwitz, Abdullah Althenayyan, Silvia Bellezza, Dante Donati, Hortense Fong, Elizabeth Friedman, Ariana Guevara, Mohamed Hussein, Kinshuk Jerath, Bruce Kogut, Kristen Lane, Hannah Li, Patryk Perkowski, Oded Netzer, Olivier Toubia</u>

arXiv:2509.19206 (cross-list from cs.DB) [pdf, other]

A decentralized future for the open-science databases

Gaurav Sharma, Viorel Munteanu, Nika Mansouri Ghiasi, Jineta Banerjee, Susheel Varma, Luca Foschini, Kyle Ellrott, Onur Mutlu, Dumitru Ciorbă, Roel A. Ophoff, Viorel Bostan, Christopher E Mason, Jason H. Moore, Despoina Sousoni, Arunkumar Krishnan, Christopher E. Mason, Mihai Dimian, Gustavo Stolovitzky, Fabio G. Liberante, Taras K. Oleksyk, Serghei Mangul

Gates Open Research

https://gatesopenresearch.org/browse/articles

[Accessed 27 Sep 2025] [Filter: All articles]

[No new digest content identified]

medRxiv

https://www.medrxiv.org/content/about-medrxiv

[Filter: All articles]
[Accessed 27 Sep 2025]

<u>Joint human and animal vaccination strategies to reach mobile pastoralists and their</u> livestock in Africa: A scoping review

Majdi M Sabahelzain, Adeline Tinessia, Catherine King, Rebika Nepali, Siddig Mohamedali, Janeth George, Victoria J Brookes, Kerrie Wiley

medRxiv 2025.09.26.25336600; doi: https://doi.org/10.1101/2025.09.26.25336600

Background: Africa's pastoralist population is approximately 268 million, which is over a quarter of the continent's population. They occupy more than 40% of Africa's land, though density varies by country. Mobile pastoralists are often underreported in national censuses due to political marginalisation and difficulties in counting these groups. Vaccination services delivered through fixed facilities do not adequately reach mobile pastoralists, which impacts vaccination coverage and health

outcomes for these mobile groups who are economically and culturally connected to their livestock. This scoping review explored literature on joint human-animal vaccination strategies as a One Health approach to improve vaccination coverage among these mobile pastoralists and their animals.

<u>Profiling Zero-Dose Measles-Rubella Children in Zambia: Insights from the 2024 Post-Campaign Coverage Survey</u>

Moses Mwale, Guissimon Phiri, Francis Dien Mwansa, Peter J. Chipimo, Penelope Masumbu, Kennedy Matanda, Princess Kayeye, Kelvin Mwangilwa, Chola Nakazwe, Harriet Namukoko, Simon Mutembo, Freddie Masaninga, Jacob Sakala, Peter Clement Lugala

medRxiv 2025.09.16.25335955; doi: https://doi.org/10.1101/2025.09.16.25335955

Vaccine Hesitancy Among Adults in India: A Systematic Review and Meta-Analysis Protocol

S Tejesh, A Y Nirupama, Varun Agiwal, Rovena Yazhini, Hotha Saisrinivas, Arijita Manna medRxiv 2025.09.23.25336433; doi: https://doi.org/10.1101/2025.09.23.25336433

<u>Factors associated with influenza vaccination among urban community-dwelling Chinese</u> <u>elderly: results from a multicity cross-sectional study</u>

Jiayue Guo, Xitong Jiao, Lili You

medRxiv 2025.08.12.25333514; doi: https://doi.org/10.1101/2025.08.12.25333514 Revision

<u>Caregivers' Qualitative Insights on Trust, Resilience and Vaccine Hesitancy Shaping Child</u> Health in Conflict-affected Northeast Nigeria

Liliana Abreu, Pia Schrage, Gbadebo Collins Adeyanju, Rabiu Ibrahim Jalo, Aisha Aliyu Abulfathi, Musa Muhammad Bello, Aminatu Ayaba Kwaku, Muhammad Ibrahim Jalo, Ahmad Mahmud, Max Schaub medRxiv 2025.09.18.25335857; doi: https://doi.org/10.1101/2025.09.18.25335857

OSF Pre-prints

https://osf.io/preprints/discover?provider=OSF&subject=bepress%7 CLife%20Sciences
[Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]
[No new digest content identified]

Wellcome Open Research

https://wellcomeopenresearch.org/browse/articles

[Accessed 27 Sep 2025]

Systematic Review Open Access

<u>Inflammation in the scar caused by BCG vaccination years previously: a case report, systematic review and critical appraisal</u>

[version 1; peer review: awaiting peer review]

Veatriki Athanasiou, Sumona Datta, Carlton A Evans

...Findings

Our systematic review of the literature concerning BCG scar inflammation did not reveal any similar reports, although anecdotally, we found that other patients have had similar experiences. We identified diverse evidence that years after BCG vaccination, antigens and/or mycobacteria remain immunologically active in BCG vaccination scars. Furthermore, mRNA COVID-19 vaccination, Kawasaki disease, acute lymphoblastic leukaemia, and immunosuppressive therapy with TNF inhibitors have all caused adults to develop inflammation in their BCG scar years or decades after childhood BCG vaccination.

Conclusions

Our systematic review, associated findings and critical appraisal demonstrate the persistence of immunologically relevant BCG mycobacteria and/or mycobacterial antigens at the site of BCG vaccination for decades after vaccination.

* * * *

Think Tanks

Brookings [to 27 Sep 2025] http://www.brookings.edu/ Research, Events No new digest content identified.

Center for Global Development [27 Sep 2025]

https://www.cgd ev.org/ All Research

WORKING PAPER

Public Childcare, Labor Market Outcomes of Caregivers, and Child Development:

Experimental Evidence from Brazil

<u>Orazio Attanasio</u> et al. September 25, 2025

This study examines the impact of publicly provided daycare for children aged 0–3 in Rio de Janeiro, where a lottery for limited slots at the end of 2007 increased time in daycare and yielded higher household incomes in the early years, sustained gains in child nutrition, and shorter-term gains in c...

Chatham House [to 27 Sep

20251

https://www.chathamhouse.org/

Selected Analysis, Comment, Events

Independent Thinking: The UN must adapt to the Trump era. How?

President Donald Trump questioned the purpose of the United Nations at the UN General Assembly this week. Our experts assess what role the organization can and should play in a changing world order.

Audio

Published 26 September 2025 30 minute listen

Featured content

Expert comment

Trump's policies and actions pose serious risks to corporate America

US democratic backsliding and diminished support for global norms may undermine investor confidence in the US and affect the ability of American companies to do business abroad. 26 September 2025 4 minute READ

Expert comment

A new international order is forming. Will China make it 'green'?

China's new climate plan announced at the UN General Assembly has a disappointing headline target – but Beijing is likely to over-deliver, and it's in its interest to place low-carbon development at the centre of its push for a new international order.

25 September 2025 4 minute READ

Council on Foreign Relations [27 Sep 2025]

https://www.cfr.org/media/news-releases
New Releases [Selected]
No new digest content identified.

CSIS [27 Sep 2025] https://www.csis.org/ Reports [Selected] No new digest content identified.

Kaiser Family Foundation/KFF [27 Sep 2025]

https://www.kff.org/search/?post_type=press-release

Newsroom

Dave A. Chokshi Joins KFF Board of Trustees

Sep 18, 2025 News Release

San Francisco – KFF announced today that Dr. Dave Ashok Chokshi, a practicing physician and health leader, has joined KFF's Board of Trustees. Dr. Chokshi is a physician at Bellevue Hospital as well as Sternberg Family Professor of Leadership at the City College of New York.

Tracking State Actions on Vaccine Policy and Access

Sep 24, 2025 Issue Brief

With recent federal actions to curtail vaccine access, many states have announced actions intended to maintain broader access. This issue brief provides a snapshot of this rapidly changing landscape, tracking which states have instituted changes in response to or in anticipation of administration policy changes.

McKinsey Global Institute [27 Sep 2025]

https://www.mckinsey.com/mgi/overview
Featured Research
No new digest content identified.

ODI [Overseas Development Institute] [to 27 Sep 2025]

https://odi.org/en/publications/ Publications [Selected] No new digest content identified.

Pew Research Center [27 Sep 2025]

https://www.pewresearch.org/ Latest Publications [Selected] No new digest content identified.

Rand [to 27 Sep 2025] https://www.rand.org/pubs.html Published Research [Selected] Research Sep 26, 2025

Exploring the Ethical Dimensions of Sequencing Newborns' Genomes: Rapid Literature and Evidence Review

The report reviews ethical, legal, and social issues of newborn genome sequencing, highlighting consent, communication, equity, governance, uncertainty, and public trust as key considerations for policy and programme design.

Sep 25, 2025

<u>Prioritizing Feasible and Impactful Actions to Enable Secure Artificial Intelligence</u> <u>Development and Use in Biology</u>

In this paper, the authors systematically evaluate actionable steps to mitigate the risk of artificial intelligence—enabled biothreat creation, providing seven priorities for further development.

Research Sep 24, 2025

<u>Understanding the Theoretical Limits of AI-Enabled Pathogen Design: Insights from a Delphi Study</u>

Concerns that artificial intelligence (AI) might enable pathogen design are increasing, but risks and timelines remain unclear. The authors report the results of a survey of experts in biology and AI on potential limits to AI-enabled pathogen design.

Expert Insights Published Sep 23, 2025

The Well-Tempered AI Assistant for Policy Processes: Approximately Optimizing AI Outputs to Empower Policy Discussions

Prompting techniques can approximately optimize artificial intelligence outputs to better align with policy objectives, stakeholder needs, and resource constraints. A violent crime reduction case study illustrates the approach.

Urban Institute [to 27 Sep 2025] https://www.urban.org/research New Research Publications - Selected No new digest content identified.

World Economic Forum [to 27 Sep 2025]

https://agenda.weforum.org/press/ Media [Selected] No new digest content identified.

::::::

Public Consultations/Call for Inputs/Call for Papers

<u>Call for Public Comment - WHO Classification of Digital Health Interventions v1.0</u> WHO 1 September 2022 **Deadline for comments: 30 September 2022, 23:59 (CEST)**Call for consultation

The World Health Organization (WHO) would like to issue a public call for comments to update v1.0 of the <u>Classification of Digital Health Interventions (CDHI)</u>. This will take the form of two public calls: Primary feedback: Call to receive public stakeholders' comments to update the Classification of Digital Health Interventions v1.0.

The WHO CDHI v1.0 was created in 2018 to provide a common digital health vocabulary for diverse stakeholders from numerous backgrounds and areas of expertise. It has since been used by stakeholders of digital health projects with a particular focus on Low and Middle-Income Countries (LMICs). As opposed to previous frameworks that provide highly technical terminology that is mainly intended for computer scientists and software developers in health, the CDHI constitutes a key bridging language between technology-oriented audiences and those in health to facilitate consistent ways of articulating needs and functionalities represented in digital health system implementations.

Since 2018, there have been advances in technology and additional interventions have arisen, prompted by the global pandemic. These, together with calls from expert communities and other stakeholders, have prompted the need to update the CDHI v1.0.

To ensure a broad consultation process, WHO will work with an expert panel and expert groups to review relevant evidence on the application of the CDHI by stakeholders and provide recommendations for update. To enable the process of the update and to ensure the input and consideration of a global group of stakeholders, WHO is issuing this public call, appealing to researchers, government and public health stakeholders, technologists, healthcare providers, donors, implementers and other agencies that utilize (or aim to utilize) the CDHI to provide comments.

Solicitation of Nominations for Appointment to the Advisory Council for the Elimination of Tuberculosis

A Notice by the Centers for Disease Control and Prevention on 07/11/2025. **Nominations must be received no later than September 30, 2025**SUMMARY:

In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), is seeking nominations for membership on the Advisory Council for the Elimination of Tuberculosis (ACET). ACET consists of 10 experts including the Chair in fields associated with public health, epidemiology, immunology, infectious disease, pulmonary disease, pediatrics, tuberculosis, microbiology, and preventive health care delivery. SUPPLEMENTARY INFORMATION:

The Advisory Council for the Elimination of Tuberculosis (ACET) provides advice and recommendations regarding the elimination of tuberculosis (TB) to the Secretary, Department of Health and Human Services (HHS); the Assistant Secretary for Health, HHS; and the Director, Centers for Disease Control and Prevention (CDC). ACET (a) makes recommendations on policies, strategies, objectives, and priorities; (b) addresses development and application of new technologies; (c) provides guidance and review of CDC's TB prevention research portfolio and program priorities; and (d) reviews the extent to which progress has been made toward eliminating TB.

Draft guideline on the quality aspects of mRNA vaccines

EMA Draft: consultation open **Consultation dates: 31/03/2025 to 30/09/2025** Reference Number: EMA/CHMP/BWP/82416/2025 *Summary:*

This guideline addresses the quality aspects of mRNA vaccines. It addresses specific aspects regarding the manufacturing process, characterisation, specifications and analytical control of mRNA vaccines, as well as the definition of starting materials, active substance and finished product for mRNA vaccines. Additional regulatory considerations are provided for changes in existing mRNA vaccine strains, bivalent and multivalent vaccines, self-amplifying mRNA vaccines, other delivery systems and use of platform technology/prior knowledge. The scope of this guideline is applicable to mRNA vaccines against infectious diseases. Other mRNA-based medicinal products are out of scope of this guideline, although relevant parts of this guideline may be applicable to those. It is not intended to address specific requirements for mRNA vaccines to be used in clinical trials, however the scientific principles described may also be applicable during pharmaceutical development.

* * * *

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: <u>Journal Watch</u>
- :: Pre-Print Servers

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the <u>GE2P2 Global Foundation</u> whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the <u>Bill & Melinda Gates Foundation</u> and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.